<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Deprescribing versus continuation of chronic proton pump inhibitor use in adults - Boghossian, TA - 2017 | Cochrane Library</title> <meta content="Deprescribing versus continuation of chronic proton pump inhibitor use in adults - Boghossian, TA - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011969.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Deprescribing versus continuation of chronic proton pump inhibitor use in adults - Boghossian, TA - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011969.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011969.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Deprescribing versus continuation of chronic proton pump inhibitor use in adults" name="citation_title"/> <meta content="Taline A Boghossian" name="citation_author"/> <meta content="The Ottawa Hospital" name="citation_author_institution"/> <meta content="Farah Joy Rashid&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="The Ottawa Hospital" name="citation_author_institution"/> <meta content="Wade Thompson" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Vivian Welch" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Paul Moayyedi" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Carlos Rojas‐Fernandez" name="citation_author"/> <meta content="University of Waterloo" name="citation_author_institution"/> <meta content="Kevin Pottie" name="citation_author"/> <meta content="Barbara Farrell" name="citation_author"/> <meta content="BFarrell@bruyere.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011969.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011969.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011969.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011969.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Deprescriptions; Esophagitis [*drug therapy]; Gastroesophageal Reflux [*drug therapy]; Inappropriate Prescribing; Patient Satisfaction [statistics &amp; numerical data]; Proton Pump Inhibitors [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011969.pub2&amp;doi=10.1002/14651858.CD011969.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="gpg7sF9V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011969\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011969\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011969.pub2",title:"Deprescribing versus continuation of chronic proton pump inhibitor use in adults",firstPublishedDate:"Mar 16, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=gpg7sF9V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011969.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011969.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011969.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011969.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011969.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011969.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011969.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011969.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011969.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011969.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12421 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011969.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/appendices#CD011969-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/table_n/CD011969StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/table_n/CD011969StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Deprescribing versus continuation of chronic proton pump inhibitor use in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0002">Taline A Boghossian</a></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0003">Farah Joy Rashid</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0004">Wade Thompson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0005">Vivian Welch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0006">Paul Moayyedi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0007">Carlos Rojas‐Fernandez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0008">Kevin Pottie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information#CD011969-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Barbara Farrell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information/en#CD011969-sec-0110">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011969.pub2">https://doi.org/10.1002/14651858.CD011969.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011969-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011969-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011969-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011969-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011969-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011969-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011969-abs-0001" lang="en"> <section id="CD011969-sec-0001"> <h3 class="title" id="CD011969-sec-0001">Background</h3> <p>Proton pump inhibitors (PPIs) are a class of medications that reduce acid secretion and are used for treating many conditions such as gastroesophageal reflux disease (GERD), dyspepsia, reflux esophagitis, peptic ulcer disease, and hypersecretory conditions (e.g. Zollinger‐Ellison syndrome), and as part of the eradication therapy for <i>Helicobacter pylori</i> bacteria. However, approximately 25% to 70% of people are prescribed a PPI inappropriately. Chronic PPI use without reassessment contributes to polypharmacy and puts people at risk of experiencing drug interactions and adverse events (e.g. <i>Clostridium difficile</i> infection, pneumonia, hypomagnesaemia, and fractures). </p> </section> <section id="CD011969-sec-0002"> <h3 class="title" id="CD011969-sec-0002">Objectives</h3> <p>To determine the effects (benefits and harms) associated with deprescribing long‐term PPI therapy in adults, compared to chronic daily use (28 days or greater). </p> </section> <section id="CD011969-sec-0003"> <h3 class="title" id="CD011969-sec-0003">Search methods</h3> <p>We searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10), MEDLINE, Embase, clinicaltrials.gov, and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). The last date of search was November 2016. We handsearched the reference lists of relevant studies. We screened 2357 articles (2317 identified through search strategy, 40 through other resources). Of these articles, we assessed 89 for eligibility. </p> </section> <section id="CD011969-sec-0004"> <h3 class="title" id="CD011969-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) and quasi‐randomized trials comparing at least one deprescribing modality (e.g. stopping PPI or reducing PPI) with a control consisting of no change in continuous daily PPI use in adult chronic users. Outcomes of interest were: change in gastrointestinal (GI) symptoms, drug burden/PPI use, cost/resource use, negative and positive drug withdrawal events, and participant satisfaction. </p> </section> <section id="CD011969-sec-0005"> <h3 class="title" id="CD011969-sec-0005">Data collection and analysis</h3> <p>Two review authors independently reviewed and extracted data and completed the risk of bias assessment. A third review author independently confirmed risk of bias assessment. We used Review Manager 5 software for data analysis. We contacted study authors if there was missing information. </p> </section> <section id="CD011969-sec-0006"> <h3 class="title" id="CD011969-sec-0006">Main results</h3> <p>The review included six trials (n = 1758). Trial participants were aged 48 to 57 years, except for one trial that had a mean age of 73 years. All participants were from the outpatient setting and had either nonerosive reflux disease or milder grades of esophagitis (LA grade A or B). Five trials investigated on‐demand deprescribing and one trial examined abrupt discontinuation. There was low quality evidence that on‐demand use of PPI may increase risk of 'lack of symptom control' compared with continuous PPI use (risk ratio (RR) 1.71, 95% confidence interval (CI) 1.31 to 2.21), thereby favoring continuous PPI use (five trials, n = 1653). There was a clinically significant reduction in 'drug burden', measured as PPI pill use per week with on‐demand therapy (mean difference (MD) ‐3.79, 95% CI ‐4.73 to ‐2.84), favoring deprescribing based on moderate quality evidence (four trials, n = 1152). There was also low quality evidence that on‐demand PPI use may be associated with reduced participant satisfaction compared with continuous PPI use. None of the included studies reported cost/resource use or positive drug withdrawal effects. </p> </section> <section id="CD011969-sec-0007"> <h3 class="title" id="CD011969-sec-0007">Authors' conclusions</h3> <p>In people with mild GERD, on‐demand deprescribing may lead to an increase in GI symptoms (e.g. dyspepsia, regurgitation) and probably a reduction in pill burden. There was a decline in participant satisfaction, although heterogeneity was high. There were insufficient data to make a conclusion regarding long‐term benefits and harms of PPI discontinuation, although two trials (one on‐demand trial and one abrupt discontinuation trial) reported endoscopic findings in their intervention groups at study end. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011969-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011969-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011969-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011969-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011969-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011969-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011969-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011969-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011969-abs-0003" lang="en"> <h3>Stopping or reducing versus continuing long‐term proton pump inhibitor use in adults</h3> <p><b>Review question</b> </p> <p>This review aimed to build on prior work and evaluate the effects of stopping or lowering the dose of proton pump inhibitors (PPIs; acid‐reducing medicines) in adults, compared to what is commonly done in practice (i.e. continuing long‐term (more than four weeks) daily PPI use. Effects include both benefits and harms (e.g. pill use, symptom control, and cost). </p> <p><b>Background</b> </p> <p>PPIs are used for many different conditions (e.g. heartburn, acid reflux, stomach ulceration). Studies for most of these conditions only support short‐term use (two to 12 weeks), yet these medicines are commonly continued for prolonged periods or even indefinitely. Long‐term PPI use contributes to medicine misuse and puts people at risk of experiencing unwanted drug interactions and side effects (e.g. diarrhea, headache, bone fractures). It also leads to a high cost burden on the healthcare system. 'Deprescribing' involves slowly withdrawing and stopping medicines. The most common approach is 'on‐demand' therapy, which allows people to use medicines only when they have symptoms (i.e. when heartburn begins). The overall goal of deprescribing is to minimize the number of medicines a person takes, thereby reducing inappropriate medicine use and avoiding side effects. </p> <p><b>Study characteristics</b> </p> <p>We found six trials with 1758 participants. Of these, five studies looked at on‐demand deprescribing and one trial looked at abruptly stopping PPIs. Participants were aged 48 to 57 years, except for one trial (average age of 73 years). The majority of participants had moderate heart burn and acid reflux with milder forms of esophagitis (inflammation of the food pipe that may lead to damage). </p> <p><b>Key results</b> </p> <p>We found that deprescribing methods led to worse symptoms control while considerably reducing pill use. Deprescribing PPIs may lead to side effects such as inflammation of the esophagus. Very few data were available to make a conclusion regarding long‐term benefits and harms of PPI reduction or discontinuation. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the quality of evidence for this review ranged from very low to moderate. Trials were inconsistent with how they reported symptom control. There were also limitations in how the studies were conducted (e.g. participants and investigators may have known which medicine they received), which lowered the quality of evidence. Other contributing factors included small sample sizes for most trials and inconsistent results between studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011969-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011969-sec-0098"></div> <h3 class="title" id="CD011969-sec-0099">Implications for practice</h3> <section id="CD011969-sec-0099"> <p>The results of this review indicate that caution is needed when implementing deprescribing methods for chronic proton pump inhibitor (PPI) users; however, few clear conclusions can be drawn regarding how to best implement PPI deprescribing. On‐demand PPI use may increase risk of symptom relapse compared to continued use, although there may be a subset of people who tolerate the intervention. If on‐demand deprescribing is tolerated, people may see a benefit of reduced pill burden by a mean of up to 3.79 pills per week. With respect the outcome of adverse drug withdrawal events (ADWE), there appears to be an increased risk of rebound esophagitis with on‐demand therapy and abrupt discontinuation, though only two trials reported data in sufficient detail. We identified no trials that allowed for conclusions regarding our primary and secondary outcomes of cost and positive drug withdrawal effects. It is important to bear in mind that the results of this systematic review only apply to people with gastroesophageal reflux disease (GERD) presenting with NERD or mild esophagitis. This excludes people with moderate‐to‐severe esophagitis, Barrett's esophagus, Zollinger‐Ellison syndrome, people with <i>H. pylori</i>, chronic NSAID use, or PUD, to name a few. </p> </section> <h3 class="title" id="CD011969-sec-0100">Implications for research</h3> <section id="CD011969-sec-0100"> <p>This systematic review highlights the paucity of high‐quality data surrounding how to deprescribe PPIs appropriately. Future trials need to focus on collecting baseline participant characteristics to illicit which specific participant characteristics predict successful PPI deprescribing outcomes. Existing literature explores a variety of deprescribing methods, though as evidenced by this review, there are few trials that compare these methods to continuous PPI therapy. Future randomized controlled trials (RCT) should compare continuous PPI therapy to deprescribing methods (i.e. abrupt discontinuation, on‐demand, and intermittent therapy) in a variety of participant populations: nonerosive GERD, erosive esophagitis (EE) (low grade), and GERD that has not been investigated endoscopically (i.e. reflective of outpatient practice in resource‐limited healthcare settings). These RCTs should also focus on capturing baseline characteristics (i.e. risk factors such as smoking, alcohol use, diet, family history). New RCTs should attempt to extend mean duration of follow‐up past one year. </p> <p>Furthermore, future research should focus on better defining costs, ADWE, and positive drug withdrawal events (PDWE). The following trial designs may address these gaps in the literature. </p> <p> <ol id="CD011969-list-0009"> <li> <p>Cost‐benefit analysis designed to quantify the costs associated with the act of deprescribing as compared to the cost‐savings associated with eliminating a lifelong therapy with an agent that is not indicated. </p> </li> <li> <p>Retrospective case‐control study to compare people who continue chronic PPI therapy as compared to people who undergo deprescribing, in order to quantify PDWE and ADWE over prolonged periods of time (i.e. greater than two years). </p> </li> <li> <p>Retrospective case‐control study to compare deprescribing outcomes in people with high‐grade EE. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011969-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011969-sec-0029"></div> <div class="table" id="CD011969-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">On‐demand deprescribing compared to continued use for people with moderate GERD and mild esophagitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>On‐demand deprescribing compared to continued use for people with moderate GERD and mild esophagitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with moderate GERD and mild esophagitis, mean age 48 to 57 years<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> on‐demand deprescribing<br/> <b>Comparison:</b> continued use </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Continued use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> On‐demand deprescribing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Lack of symptom control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.71</b> <br/> (1.31 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1653<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> <br/> (120 to 203) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> <br/> (161 to 272) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pill use (pills/week)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pill use (pills/week) in the intervention groups was<br/> <b>3.79 lower</b> <br/> (4.73 to 2.84 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1152<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost/resource use</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We found no data on cost or resource use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse drug withdrawal events ‐ esophagitis (endoscopic findings)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 30.59</b> </p> <p>(1.84 to 508.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>598<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk not estimable as no events in continued use arm.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.82</b> <br/> (1.26 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1653<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (111 to 234) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b> <br/> (102 to 215) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>GERD:</b> gastroesophageal reflux disease; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to a high risk of detection bias, and attrition bias.<br/> <sup>2</sup> Downgraded one level due to wide confidence intervals and summary statistic close to the line of no effect.<br/> <sup>3</sup> Downgraded one level due to high risk of detection and attrition bias.<br/> <sup>4</sup> Downgraded one level due to high risk of attrition and reporting bias.<br/> <sup>5</sup> Downgraded one level due to indirectness as poor methods of satisfaction used (willingness to continue or "inadequate relief"). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011969-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Abrupt discontinuation deprescribing compared to continued use for people with mild‐to‐moderate esophagitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Abrupt discontinuation deprescribing compared to continued use for people with mild to moderate esophagitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild to moderate esophagitis, symptomatic, aged &gt; 18 years (mean age 73 years)<br/> <b>Settings: o</b> utpatient<br/> <b>Intervention:</b> abrupt discontinuation deprescribing<br/> <b>Comparison:</b> continued use </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Continued use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Abrupt discontinuation deprescribing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Lack of symptom control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.02</b> <br/> (1.74 to 5.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>105<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>678 per 1000</b> <br/> (391 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b> <br/> (392 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse drug withdrawal events ‐ relapse (endoscopic findings)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.41</b> <br/> (1.91 to 6.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>105<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>696 per 1000</b> <br/> (390 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>696 per 1000</b> <br/> (390 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to concerns surrounding attrition bias and blinding.<br/> <sup>2</sup> Downgraded two levels due to wide confidence intervals, and small number of participants and events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011969-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011969-sec-0030"></div> <p>See <a href="./appendices#CD011969-sec-0104">Appendix 1</a> for a glossary of terms and <a href="./appendices#CD011969-sec-0105">Appendix 2</a> for abbreviations used in this review. </p> <p>Proton pump inhibitors (PPIs) are a class of medications that reduce acid secretion by inhibiting gastric H<sup>+</sup>, K<sup>+</sup>‐adenosine triphosphatase (ATPase). They are used for treating many conditions such as gastroesophageal reflux disease (GERD), dyspepsia (i.e. indigestion), reflux esophagitis (inflammation of the esophagus), peptic ulcer disease (PUD), hypersecretory conditions (e.g. Zollinger‐Ellison syndrome), and as part of the eradication therapy for <i>Helicobacter pylori</i> (<i>H. pylori</i>) bacteria (<a href="./references#CD011969-bbs2-0146" title="WallaceJL , SharkeyKA . Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. In: BruntonLL , ChabnerBA , KnollmanCB editor(s). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw‐Hill, 2011:1309‐22. ">Wallace 2011</a>). They are also used to prevent and reduce the risk of ulcers in people with a history of PUD, in critically ill people as stress ulcer prophylaxis (SUP), and people who use chronic nonsteroidal anti‐inflammatory drugs (NSAIDs) (<a href="./references#CD011969-bbs2-0093" title="ArmstrongTA , CoursinDB , DevlinJ , DukeJS , FishD , GonzalezER , et al. ASHP therapeutic guidelines on stress ulcer prophylaxis. American Journal of Health‐System Pharmacy. United States: American Society of Health‐Systems Pharmacy, 1999; Vol. 56, issue 4:347‐79. ">Armstrong 1999</a>; <a href="./references#CD011969-bbs2-0094" title="ArmstrongD , MarshallJK , ChibaN , EnnsR , FalloneCA , FassR , et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults ‐ update 2004. Canadian Journal of Gastroenterology2005;19(1):15‐35. ">Armstrong 2005</a>). </p> <section id="CD011969-sec-0031"> <h3 class="title" id="CD011969-sec-0031">Description of the condition</h3> <section id="CD011969-sec-0032"> <h4 class="title">Gastroesophageal reflux disease</h4> <p>GERD affects millions of adults globally. Approximately five million Canadians experience heartburn or regurgitation (or both) at least once weekly, where heartburn is the most common symptom reported (17%) followed by regurgitation (11%) (<a href="./references#CD011969-bbs2-0096" title="Canadian Digestive Health Foundation. GERD, 2015. www.cdhf.ca/en/statistics (accessed 9 November 2015). ">CDHF 2015</a>; <a href="./references#CD011969-bbs2-0141" title="TougasG , ChenY , HwangP , LiuMM , EgglestonA . Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. American Journal of Gastroenterology1999;94(10):2845‐54. ">Tougas 1999</a>). Similar figures also extend globally. One systematic review evaluating the epidemiology of GERD found that 10% to 20% of adults in Western countries are also affected by GERD (<a href="./references#CD011969-bbs2-0101" title="DentJ , El‐SeragHB , WallanderMA , JohanssonS . Epidemiology of gastro‐oesophageal reflux disease: a systematic review. Gut2005;54(5):710‐7. ">Dent 2005</a>). </p> <p>Many GERD publications and guidelines exist though a uniform definition of GERD among them is lacking. The Canadian Consensus on the Management of Gastroesophageal Reflux Disease in Adults (Canadian Consensus) defines GERD as the "reflux of gastric contents into the esophagus causing (a) symptoms sufficient to reduce quality of life, and/or (b) esophageal injury". The hallmark symptoms are heartburn and acid regurgitation. The Canadian Consensus also classifies GERD as either 'mild' or 'moderate and severe' disease (<a href="./references#CD011969-bbs2-0094" title="ArmstrongD , MarshallJK , ChibaN , EnnsR , FalloneCA , FassR , et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults ‐ update 2004. Canadian Journal of Gastroenterology2005;19(1):15‐35. ">Armstrong 2005</a>). The American College of Gastroenterology's (ACG) Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease recognizes that GERD is "defined by consensus and as such is a disease comprising symptoms, end‐organ effects and complications related to the reflux of gastric contents into the esophagus, oral cavity and/or the lung" (<a href="./references#CD011969-bbs2-0119" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. United Kingdom: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom), 2013; Vol. 108, issue 3:308‐28. ">Katz 2013</a>). The ACG categorizes GERD based on endoscopic findings: nonerosive GERD (NERD) is symptomatic GERD with negative endoscopy, while GERD with erosive findings on endoscopy is referred to as erosive reflux disease or erosive esophagitis (EE) (<a href="./references#CD011969-bbs2-0119" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. United Kingdom: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom), 2013; Vol. 108, issue 3:308‐28. ">Katz 2013</a>). In 2006, the Global Consensus Group published the Montreal Definition and Classification of GERD to determine a globally acceptable definition that would be useful for patients, practitioners, and health agencies. This group defined GERD as, "a condition which develops when the reflux of stomach contents cause troublesome symptoms and/or complications", such as heartburn, regurgitation, and esophageal injury (i.e. reflux esophagitis) (<a href="./references#CD011969-bbs2-0142" title="VakilN , VanZantenSV , KahrilasP , DentJ , JonesR , BianchiLK , et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence‐based consensus. American Journal of Gastroenterology2006;101(8):1900‐20. ">Vakil 2006</a>). </p> </section> <section id="CD011969-sec-0033"> <h4 class="title">Reflux esophagitis</h4> <p>PPIs are also commonly used on a long‐term basis for esophagitis due to chronic GERD. The severity of EE detected on endoscopy is classified by the Los Angeles (LA) Grading criteria as grades A to D, defined as follows: grade A ‐ at least one mucosal break of 5 mm or less, not extending between the tops of two mucosal folds; grade B ‐ at least one mucosal break with a length greater than 5 mm not extending between the tops of two mucosal folds; grade C ‐ at least one mucosal break involving less than 75% of the esophageal circumference, but extending between the tops of at least two mucosal folds; grade D ‐ at least one mucosal break involving 75% or more of the esophageal circumference (<a href="./references#CD011969-bbs2-0124" title="LundellLR , DentJ , BennettJR , BlumAL , ArmstrongD , GalmicheJP , et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut1999;45(2):172‐80. ">Lundell 1999</a>). LA Grade C and D esophagitis are considered severe stages of esophagitis, have lower rates of healing with PPIs, and are more prone to relapse in the absence of maintenance therapy (<a href="./references#CD011969-bbs2-0119" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. United Kingdom: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom), 2013; Vol. 108, issue 3:308‐28. ">Katz 2013</a>). The Canadian Dyspepsia Working Group suggest that healing and symptom relief of EE is superior with PPIs as compared to histamine H2 receptor antagonists (H<sub>2</sub>RAs), and that standard doses of PPIs are superior to half or low doses of PPIs for this indication (<a href="./references#CD011969-bbs2-0144" title="Veldhuyzen van ZantenSJO , BradetteM , ChibaN , ArmstrongD , BarkunA , FlookN , et al. Evidence‐based recommendations for short‐ and long‐term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Canadian Journal of Gastroenterology2005;19(5):285‐303. ">Veldhuyzen van Zanten 2005</a>). Barrett's esophagus is another long‐term sequelae of GERD and esophagitis that is believed to be developed from the change of normal esophageal epithelial cells to specialized intestinal glandular epithelial cells. This metaplasia, detectable via endoscopy, can progress to dysplasia, and finally adenocarcinoma (<a href="./references#CD011969-bbs2-0094" title="ArmstrongD , MarshallJK , ChibaN , EnnsR , FalloneCA , FassR , et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults ‐ update 2004. Canadian Journal of Gastroenterology2005;19(1):15‐35. ">Armstrong 2005</a>). The ACG guidelines recommend ongoing maintenance PPI therapy for people with EE and Barrett's esophagus (<a href="./references#CD011969-bbs2-0119" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. United Kingdom: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom), 2013; Vol. 108, issue 3:308‐28. ">Katz 2013</a>). Since Barrett's esophagus is believed to result from chronic acid reflux, the Canadian guidelines suggest that regardless of symptoms, it should be treated with lifelong PPIs of at least standard dose, and managed by specialists (<a href="./references#CD011969-bbs2-0144" title="Veldhuyzen van ZantenSJO , BradetteM , ChibaN , ArmstrongD , BarkunA , FlookN , et al. Evidence‐based recommendations for short‐ and long‐term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Canadian Journal of Gastroenterology2005;19(5):285‐303. ">Veldhuyzen van Zanten 2005</a>). </p> </section> <section id="CD011969-sec-0034"> <h4 class="title">Peptic ulcer disease</h4> <p>Gastric and duodenal ulcers (bleeding or nonbleeding) are often referred to under the rubric of PUD (<a href="./references#CD011969-bbs2-0090" title="Alberta Clinical Practice Guideline Working Group. Guideline for diagnosis and treatment of chronic undiagnosed dyspepsia in adults. The Alberta Clinical Guideline Program2000; Vol. June:1‐10. ">ACPG 2000</a>; <a href="./references#CD011969-bbs2-0119" title="KatzPO , GersonLB , VelaMF . Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. United Kingdom: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom), 2013; Vol. 108, issue 3:308‐28. ">Katz 2013</a>; <a href="./references#CD011969-bbs2-0139" title="TalleyNJ , VakilN . Guidelines for the management of dyspepsia. American Journal of Gastroenterology2005;100(10):2324‐37. ">Talley 2005</a>). There are many risk factors and possible causes for PUD, the most common being infection of the gastric mucosa with <i>H. pylori</i> ; however, other causes include NSAID‐ or drug‐induced PUD, and hypersecretory states. The standard for <i>H. pylori‐</i>positive PUD is treatment with triple therapy (two antibiotics and one PPI) to eradicate the bacteria. This is typically followed by four to eight weeks of PPI therapy for gastric ulcers, but does not require subsequent PPI therapy in the setting of uncomplicated duodenal ulcers. If eradication is achieved, the rate of rebleeding is very low (1.3% over 11 to 53 months) (<a href="./references#CD011969-bbs2-0108" title="GisbertJP , KhorramiS , CarballoF , CalvetX , GeneE , Dominguez‐MunozE . Meta‐analysis: Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Alimentary Pharmacology &amp; Therapeutics2004;19(6):617‐29. ">Gisbert 2004</a>; <a href="./references#CD011969-bbs2-0120" title="LaineL , JensenDM . Management of patients with ulcer bleeding. American Journal of Gastroenterology2012;107(3):345‐61. ">Laine 2012</a>; <a href="./references#CD011969-bbs2-0125" title="MalfertheinerP , Chan FrancisKL , McColl KennethEL . Peptic ulcer disease. Lancet2009;374(9699):1449‐61. ">Malfertheiner 2009</a>). </p> <p>NSAIDs, and to a lesser extent newer selective cyclooxygenase‐2 (COX2) inhibitors, are known to cause dyspeptic symptoms and increase the risk of PUD through the inhibition of cyclooxygenase‐1 (COX1) enzyme in the gastric mucosa. There is support for the concomitant use of gastroprotective agents (PPIs, misoprostol, or H<sub>2</sub>RAs) as primary or secondary prophylaxis of peptic ulcers, especially in the presence of risk factors. These include age 65 years or over; history of bleeding PUD; and use of corticosteroids, anticoagulants, or antiplatelet agents (<a href="./references#CD011969-bbs2-0144" title="Veldhuyzen van ZantenSJO , BradetteM , ChibaN , ArmstrongD , BarkunA , FlookN , et al. Evidence‐based recommendations for short‐ and long‐term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Canadian Journal of Gastroenterology2005;19(5):285‐303. ">Veldhuyzen van Zanten 2005</a>). If people are to be maintained on long‐term NSAID therapy, it is advised to test and treat for <i>H. pylori</i> due to the additive risk (<a href="./references#CD011969-bbs2-0144" title="Veldhuyzen van ZantenSJO , BradetteM , ChibaN , ArmstrongD , BarkunA , FlookN , et al. Evidence‐based recommendations for short‐ and long‐term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Canadian Journal of Gastroenterology2005;19(5):285‐303. ">Veldhuyzen van Zanten 2005</a>). </p> </section> </section> <section id="CD011969-sec-0035"> <h3 class="title" id="CD011969-sec-0035">Description of the intervention</h3> <p>'Deprescribing' involves slowly withdrawing and stopping medications, with the aim of reducing polypharmacy and inappropriate medication use thereby improving people's outcomes (<a href="./references#CD011969-bbs2-0140" title="ThompsonW , FarrellB . Deprescribing: what is it and what does the evidence tell us?. Canadian Journal of Hospital Pharmacy2013;66(3):201‐2. ">Thompson 2013</a>). A number of approaches to deprescribing have been outlined by the Canadian Consensus: intermittent PPI use is defined as a "daily intake of a medication for a predetermined, finite period (usually two to eight weeks) to produce resolution of reflux‐related symptoms or healing of esophageal lesions following relapse of the individual's condition"; on‐demand PPI use is defined as "the daily intake of a medication for a period sufficient to achieve resolution of the individual's reflux‐related symptoms; following symptom resolution, the medication is discontinued until the individual's symptoms recur, at which point, medication is again taken daily until the symptoms resolve" (<a href="./references#CD011969-bbs2-0094" title="ArmstrongD , MarshallJK , ChibaN , EnnsR , FalloneCA , FassR , et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults ‐ update 2004. Canadian Journal of Gastroenterology2005;19(1):15‐35. ">Armstrong 2005</a>). Other deprescribing methods may include stopping therapy abruptly or via a tapering regimen, switching to an alternate therapy (e.g. stepping down from PPI to H<sub>2</sub>RA), lowering the total daily dose, or, in the case of active <i>H.</i> pylori infection, treating the infection and then discontinuing PPI therapy. </p> <p>Small studies have demonstrated successful deprescribing approaches, yet currently no systematically developed guidelines exist that describe known benefits and harms of deprescribing (<a href="./references#CD011969-bbs2-0109" title="GnjidicD , LeCouteurDG , KouladjianL , HilmerSN . Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clinics in Geriatric Medicine2012;28(2):237‐53. ">Gnjidic 2012</a>; <a href="./references#CD011969-bbs2-0117" title="IyerS , NaganathanV , McLachlanAJ , LeCouteurDG . Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs and Aging. New Zealand: Adis International Ltd, 2008; Vol. 25, issue 12:1021‐31. ">Iyer 2008</a>). Furthermore, there are no evidence‐based methods of stopping (i.e. tapering and monitoring) specific drugs to help guide prescribers and other clinicians. </p> <p>The concept of deprescribing is straightforward, yet many barriers exist for clinicians and patients (<a href="./references#CD011969-bbs2-0130" title="RaghunathAS , HunginAPS , CornfordCS , FeatherstoneV . Use of proton pump inhibitors: an exploration of the attitudes, knowledge and perceptions of general practitioners. Digestion2005;72(4):212‐8. ">Raghunath 2005</a>; <a href="./references#CD011969-bbs2-0131" title="ReeveE , WieseMD . Difficulties reducing inappropriate prescribing of proton pump inhibitors in the elderly. Drugs &amp; Aging2012;29(11):925‐8. ">Reeve 2012</a>; <a href="./references#CD011969-bbs2-0132" title="ReeveE , ToJ , HendrixI , ShakibS , RobertsMS , WieseMD . Patient barriers to and enablers of deprescribing: a systematic review. Drugs &amp; Aging2013;30(10):793‐807. ">Reeve 2013</a>). Barriers include: clinician internal pressures (i.e. believing drug therapy is effective, safe, and recommended, and desire to prescribe it), clinician workload pressures (i.e. desire to avoid repeat consultations), patient pressures (i.e. people requesting therapy or unwilling to stop an effective treatment or switch to an alternative), and marketing and commercial influences. Additionally, clinicians and patients may disagree with the appropriateness of deprescribing, possibly related to belief of lack of suitable alternatives, fear of return or worsening of a person's symptoms, and influences of negative past experiences or experiences of others. Clinicians also believe that patients may be unwilling to discontinue PPIs as it allows for continued adverse lifestyle habits that contribute to GERD symptoms (e.g. smoking or poor diet), although this has not been confirmed by existing literature (<a href="./references#CD011969-bbs2-0112" title="GrimeJ , PollockK , BlenkinsoppA . Proton pump inhibitors: perspectives of patients and their GPs. British Journal of General Practice2001;51(470):703‐11. ">Grime 2001</a>). Clinicians may also be reluctant to discontinue medications initiated by other health professionals. The lack of guidelines and fear/concern of withdrawal or rebound symptoms are key concerns limiting the implementation of deprescribing initiatives. In addition, polypharmacy often is not addressed, with adverse drug effects being mistaken for new conditions requiring additional treatment, thus driving the cycle of inappropriate prescribing (<a href="./references#CD011969-bbs2-0092" title="AnthierensS , TansensA , PetrovicM , ChristiaensT . Qualitative insights into general practitioners views on polypharmacy. BMC Family Practice2010;11:65. ">Anthierens 2010</a>; <a href="./references#CD011969-bbs2-0116" title="HilmerSN , GnjidicD . The effects of polypharmacy in older adults. Clinical Pharmacology and Therapeutics2009;85(1):86‐8. ">Hilmer 2009</a>). </p> </section> <section id="CD011969-sec-0036"> <h3 class="title" id="CD011969-sec-0036">How the intervention might work</h3> <p>Various deprescribing methods exist. While the underlying goal of deprescribing is the same (i.e. to stop or reduce in an attempt to discontinue or achieve the lowest effective dose), the methods and outcomes may differ. Different methods for reducing drug exposure have been reported (e.g. pharmacist‐led medication reviews, prescriber feedback, and multidisciplinary interventions), though their resulting clinical outcomes are not always reported (<a href="./references#CD011969-bbs2-0109" title="GnjidicD , LeCouteurDG , KouladjianL , HilmerSN . Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clinics in Geriatric Medicine2012;28(2):237‐53. ">Gnjidic 2012</a>). Such outcomes include positive drug withdrawal events (PDWE) and adverse drug withdrawal events (ADWE). Graves and colleagues defined ADWE as a "clinically significant set of signs or symptoms caused by the removal of a drug" (<a href="./references#CD011969-bbs2-0111" title="GravesT , HanlonJT , SchmaderKE , LandsmanPB , SamsaGP , PieperCF , et al. Adverse events after discontinuing medications in elderly outpatients. Archives of Internal Medicine1997;157(19):2205‐10. ">Graves 1997</a>). Indeed, ADWEs are major contributors to unsuccessful deprescribing. In contrast, desirable outcomes (i.e. reduction/elimination of potential or actual drug‐related adverse events) may result from drug withdrawals, which will be referred to in this review as PDWEs. Successful deprescribing may also result in reduced drug interactions, increased quality of life and patient satisfaction, as well as reduced drug burden and costs. </p> <p>Stopping PPIs by abrupt withdrawal or by slowly withdrawing or reducing the dose has been theorized to have beneficial effects, as well as potential harms. As suggested by Linsky and colleagues, PPIs are often viewed as having few adverse effects; however, their long‐term use has been associated with an increased risk of pneumonia, <i>Clostridium difficile</i> (<i>C. difficile</i>) colitis, and osteoporotic fractures (<a href="./references#CD011969-bbs2-0123" title="LinskyA , SimonSR . Reversing gears: discontinuing medication therapy to prevent adverse events. JAMA Internal Medicine2013;173(7):524‐5. ">Linsky 2013</a>). Limiting PPI doses or stopping PPIs via one of the three interventions that will be assessed in this review may reduce the risk of such adverse events. </p> <p>One Cochrane review by Donnellan and colleagues investigated comparative efficacies of various therapies (including PPIs) in preventing relapse in people with esophagitis and endoscopy‐negative reflux disease (<a href="./references#CD011969-bbs2-0103" title="DonnellanC , PrestonC , MoayyediP , SharmaN . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews2004, issue 4:CD003245. [DOI: 10.1002/14651858.CD003245.pub2] ">Donnellan 2004</a>). The current review adds to the knowledge established by <a href="./references#CD011969-bbs2-0103" title="DonnellanC , PrestonC , MoayyediP , SharmaN . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews2004, issue 4:CD003245. [DOI: 10.1002/14651858.CD003245.pub2] ">Donnellan 2004</a>, by including additional indications for PPI use, and focusing on trials that allow for comparison of different maintenance therapy strategies with a control of no change in continuous PPI use. </p> <p>One systematic review by Lee and colleagues evaluated whether people with GERD were receiving unnecessary maintenance PPI therapy or high‐dose PPI therapy (<a href="./references#CD011969-bbs2-0121" title="LeeTJ , FennertyMB , HowdenCW . Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease?. Alimentary Pharmacology &amp; Therapeutics2004;20(11‐12):1241‐51. ">Lee 2004</a>). The review included deprescribing trials, including randomized controlled trials (RCTs) and nonrandomized trials, of switching to H<sub>2</sub>RA, intermittent or on‐demand PPI use, and dose reduction of high‐dose PPIs. The review reported that 80% of people receiving high‐dose PPIs were able to reduce their doses successfully to standard‐dose PPIs. Based on results of participant symptom assessments, deprescribing was possible in 26% to 71% of people with GERD (<a href="./references#CD011969-bbs2-0121" title="LeeTJ , FennertyMB , HowdenCW . Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease?. Alimentary Pharmacology &amp; Therapeutics2004;20(11‐12):1241‐51. ">Lee 2004</a>). Despite these results, it remains unclear how the deprescribing interventions evaluated by Lee and colleagues compare to people who would continue on long‐term PPI therapy (e.g. without a change in dose), and which benefits or risks exist with deprescribing. </p> <p><a href="./references#CD011969-bbs2-0118" title="JiangY‐X , ChenY , KongX , TongY‐L , XuS‐C . Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on‐demand: a meta‐analysis. Hepato‐gastroenterology2013;60(125):1077‐82. ">Jiang 2013</a> undertook another systematic review and meta‐analysis of on‐demand PPI. This group measured the proportion of people who were unwilling to continue on‐demand therapy compared to people unwilling to continue on daily PPI therapy or placebo. They found that on‐demand therapy reduced the risk of being unwilling to continue compared to daily PPI therapy and placebo. This meta‐analysis did not report on other outcomes such as pill burden, ADWEs, or symptom relapse and may not have included all studies relevant for our review. Further, most people in practice will continue on the same dose of PPI long‐term. Studies in the <a href="./references#CD011969-bbs2-0118" title="JiangY‐X , ChenY , KongX , TongY‐L , XuS‐C . Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on‐demand: a meta‐analysis. Hepato‐gastroenterology2013;60(125):1077‐82. ">Jiang 2013</a> meta‐analysis did not compare people with on‐demand PPI use to people who continued on the same dose of PPI long‐term with no change in regimen. As such, the effect of on‐demand use compared to continued PPI use is not well‐established. </p> <p>The present systematic review builds on prior work and evaluates evidence of deprescribing compared to what is commonly done in practice, that is, continuing chronic PPI use with no change in regimen. </p> </section> <section id="CD011969-sec-0037"> <h3 class="title" id="CD011969-sec-0037">Why it is important to do this review</h3> <p>The evidence for PPI use in many indications (e.g. GERD, PUD, SUP) only supports short‐term use (e.g. two to 12 weeks), yet these drugs are commonly continued for prolonged periods or even indefinitely, without appropriate reassessment (<a href="./references#CD011969-bbs2-0103" title="DonnellanC , PrestonC , MoayyediP , SharmaN . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews2004, issue 4:CD003245. [DOI: 10.1002/14651858.CD003245.pub2] ">Donnellan 2004</a>; <a href="./references#CD011969-bbs2-0134" title="ReimerC , BytzerP . Clinical trial: long‐term use of proton pump inhibitors in primary care patients ‐ a cross sectional analysis of 901 patients. Alimentary Pharmacology &amp; Therapeutics2009;30(7):725‐32. ">Reimer 2009a</a>). </p> <p>Continuous use of PPIs for durations exceeding accepted standards appears to be commonplace, and is likely because they are very well tolerated and considered benign compared to other prescribed medications. This relatively desirable safety profile often overshadows lesser known drug interactions (e.g. hepatic enzyme inhibition, effects on drug absorption or activation) and poorly understood adverse effects and associated risks (vitamin B<sub>12</sub> deficiency, hypomagnesemia, community‐acquired pneumonia (CAP), <i>C. difficile</i> infection, diarrhea, headache, and fractures) (<a href="./references#CD011969-bbs2-0091" title="AmentPW , DicolaDB , JamesME . Reducing adverse effects of proton pump inhibitors. American Family Physician2012;86(1):66‐70. ">Ament 2012</a>; <a href="./references#CD011969-bbs2-0098" title="ChubinehS , BirkJ . Proton pump inhibitors: the good, the bad, and the unwanted. Southern Medical Journal2012;105(11):613‐8. ">Chubineh 2012</a>; <a href="./references#CD011969-bbs2-0104" title="FohlAL , RegalRE . Proton pump inhibitor‐associated pneumonia: not a breath of fresh air after all?. World Journal of Gastrointestinal Pharmacology and Therapeutics2011;2(3):17‐26. ">Fohl 2011</a>; <a href="./references#CD011969-bbs2-0123" title="LinskyA , SimonSR . Reversing gears: discontinuing medication therapy to prevent adverse events. JAMA Internal Medicine2013;173(7):524‐5. ">Linsky 2013</a>). Although these adverse effects may not be very common and true association with risk is debatable, the extensive use of PPIs in a wide range of populations without monitoring and reassessment is concerning. </p> <p>The Canadian Health Network reported that six PPIs were in the top 100 prescribed drugs in 2012, with pantoprazole ranking fifth at 11,051,000 prescriptions dispensed in Canadian retail pharmacies over a 12‐month period (<a href="./references#CD011969-bbs2-0097" title="Canadian Healthcare Network. Top 100 Drugs. Pharmacy Practice2013, issue March:1‐25. ">CHN 2013</a>). Due to this widespread and chronic use, even rare adverse events will present over time and put people at risk. </p> <p>Inappropriate PPI use is not only commonplace in Canada, it is also a major global issue. It is estimated that between 20% and 82% of people worldwide are using a PPI without an indication (<a href="./references#CD011969-bbs2-0099" title="ClaudeneGJ , BeatrizK , JosephRS . Appropriate proton pump inhibitor use among older adults: a retrospective chart review. American Journal of Geriatric Pharmacotherapy2008;6(5):249‐54. ">Claudene 2008</a>; <a href="./references#CD011969-bbs2-0100" title="DanglerM , OchsL , WhiteR . Assessing the appropriate use of proton pump inhibitors in a veteran outpatient population. Federal Practitioner2013;30(5):21‐5. ">Dangler 2013</a>; <a href="./references#CD011969-bbs2-0114" title="HeidelbaughJJ , GoldbergKL , InadomiJM . Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. American Journal of Managed Care2010;16(9):e228‐34. ">Heidelbaugh 2010</a>; <a href="./references#CD011969-bbs2-0122" title="LeriF , AyzenbergM , VoyceSJ , KleinA , HartzL , SmegoRA . Four‐year trends of inappropriate proton pump inhibitor use after hospital discharge. Southern Medical Association2013;106(4):270‐3. ">Leri 2013</a>; <a href="./references#CD011969-bbs2-0126" title="MolloyD , MolloyA , O'LoughlinC , FalconerM , HennessyM . Inappropriate use of proton pump inhibitors. Irish Journal of Medical Science2010;179(1):73‐5. ">Molloy 2010</a>; <a href="./references#CD011969-bbs2-0133" title="ReeveE , AndrewsJM , WieseMD , HendrixI , RobertsMS , ShakibS . Feasibility of a patient‐centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Annals of Pharmacotherapy2015;49(1):29‐38. ">Reeve 2015</a>; <a href="./references#CD011969-bbs2-0145" title="WahabMSA , Nyfort‐HansenK , KowalskiSR . Inappropriate prescribing in hospitalised Australian elderly as determined by the STOPP criteria. International Journal of Clinical Pharmacy2012;34(6):855‐62. ">Wahab 2012</a>). For example, in one cross‐sectional study of people in primary care in Denmark receiving long‐term PPI therapy, 39% had never undergone a trial withdrawal, and only 27% had a verified diagnosis indicating the need for PPI therapy (<a href="./references#CD011969-bbs2-0134" title="ReimerC , BytzerP . Clinical trial: long‐term use of proton pump inhibitors in primary care patients ‐ a cross sectional analysis of 901 patients. Alimentary Pharmacology &amp; Therapeutics2009;30(7):725‐32. ">Reimer 2009a</a>). These findings also parallel those of one Australian study (<a href="./references#CD011969-bbs2-0106" title="GadzhanovaSV , RougheadEE , MacksonJM . Initiation and duration of proton pump inhibitors in the Australian veteran population. Internal Medicine Journal2012;42(5):e68‐73. ">Gadzhanova 2012</a>). The Gastroenterological Society of Australia (GESA) make specific recommendations to consider 'stepdown' therapy, cessation, or dose reduction, in targeted populations (e.g. milder grades of esophagitis or mild reflux symptoms) (<a href="./references#CD011969-bbs2-0107" title="Gastroenterological Society of Australia. Gastro‐oesophageal Reflux Disease in Adults. 5th Edition. Mulgrave, Australia: Digestive Health Foundation, 2011:10. ">GESA 2011</a>), yet, <a href="./references#CD011969-bbs2-0106" title="GadzhanovaSV , RougheadEE , MacksonJM . Initiation and duration of proton pump inhibitors in the Australian veteran population. Internal Medicine Journal2012;42(5):e68‐73. ">Gadzhanova 2012</a> found that only one‐third of people initiated on high‐dose PPIs were stepped down, as per GESA recommendations. </p> <p>Another example of inappropriate PPI therapy includes continuation of SUP after discharge from various intensive care unit (ICU) settings in the US (<a href="./references#CD011969-bbs2-0114" title="HeidelbaughJJ , GoldbergKL , InadomiJM . Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. American Journal of Managed Care2010;16(9):e228‐34. ">Heidelbaugh 2010</a>). Guidelines suggest use of SUP (PPI or H<sub>2</sub>RA) in critically ill people with coagulopathy, mechanical ventilation for more than 48 hours, or a history of gastrointestinal (GI) ulceration or bleed within the last year (<a href="./references#CD011969-bbs2-0093" title="ArmstrongTA , CoursinDB , DevlinJ , DukeJS , FishD , GonzalezER , et al. ASHP therapeutic guidelines on stress ulcer prophylaxis. American Journal of Health‐System Pharmacy. United States: American Society of Health‐Systems Pharmacy, 1999; Vol. 56, issue 4:347‐79. ">Armstrong 1999</a>; <a href="./references#CD011969-bbs2-0138" title="SpirtMJ , StanleyS . Update on stress ulcer prophylaxis in critically ill patients. Critical Care Nurse2006;26(1):18‐29. ">Spirt 2006</a>). However, many people continue SUP therapy after discharge when it is no longer indicated. Murphy and colleagues published a study demonstrating this in people in surgical ICUs (<a href="./references#CD011969-bbs2-0127" title="MurphyCE , StevensAM , FerrentinoN , CrookesBA , HebertJC , FreiburgCB , et al. Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy2008;28(8):968‐76. ">Murphy 2008</a>). The authors concluded that PPIs and H<sub>2</sub>RAs were continued in 24.2% of people upon discharge from hospital. </p> <p>Leri and colleagues also described PPI misuse<i>.</i> The authors conducted a retrospective review to identify PPI continuation at discharge in people who had a PPI initiated in hospital. The authors reported 78% to 82% of people were discharged on a PPI inappropriately between 2005 and 2008 (<a href="./references#CD011969-bbs2-0122" title="LeriF , AyzenbergM , VoyceSJ , KleinA , HartzL , SmegoRA . Four‐year trends of inappropriate proton pump inhibitor use after hospital discharge. Southern Medical Association2013;106(4):270‐3. ">Leri 2013</a>). </p> <p>The overuse of PPIs has also led to tremendous costs. The Canadian Health Network report listed eight brands of PPIs in the top 100 products based on prescription cost (<a href="./references#CD011969-bbs2-0097" title="Canadian Healthcare Network. Top 100 Drugs. Pharmacy Practice2013, issue March:1‐25. ">CHN 2013</a>). Esomeprazole (Nexium) ranked at seven with a cost of CAD 257,173,000 for the cited 12‐month period (<a href="./references#CD011969-bbs2-0097" title="Canadian Healthcare Network. Top 100 Drugs. Pharmacy Practice2013, issue March:1‐25. ">CHN 2013</a>). In one 2007 Canadian Agency for Drugs and Technologies in Health (CADTH) report on economics surrounding treatment of dyspepsia and GERD compared five treatment regimens: on‐demand H<sub>2</sub>RA, on‐demand PPI, maintenance H<sub>2</sub>RA, maintenance PPI, and PPI with stepdown to H<sub>2</sub>RA (<a href="./references#CD011969-bbs2-0095" title="Canadian Agency for Drugs and Technologies in Health. Economic models and conclusions for the treatment of dyspepsia; and gastroesophageal reflux disease‐related heartburn and the prevention of non‐steroidal anti‐inflammatory drug‐induced gastrointestinal complications, 2007. www.cadth.ca/sites/default/files/compus/pdf/compus_economic_report_april‐07_e.pdf (accessed 9 November 2015). ">CADTH 2007</a>). In the setting of EE and investigated GERD, on‐demand PPI therapy had the lowest expected one‐year costs (CAD 537/year for EE and CAD 635/year for GERD) compared with maintenance PPI treatment, which had the highest estimated cost (CAD 776/year for EE and CAD 816/year for GERD; estimates based on 2006 Ontario costs). In the NERD population, the most cost‐effective strategy was on‐demand H<sub>2</sub>RA (CAD 641/year) and the most costly strategy remained maintenance PPI therapy (CAD 827/year). In terms of efficacy, the report documented "expected weeks with heartburn" for each therapy. In all three populations, maintenance PPI therapy resulted in the lowest number of weeks with heartburn, followed second in all instances by PPI with stepdown to H<sub>2</sub>RA. The least effective treatment in all populations was on‐demand H<sub>2</sub>RA. </p> <p>Several western countries have also reported high expenditure on PPIs. In 2006, GBP 425 million was spent on PPIs in England, and the same issue extends globally to GBP 7 billion (<a href="./references#CD011969-bbs2-0105" title="ForgacsI , LoganayagamA . Overprescribing proton pump inhibitors. BMJ (Clinical Research Ed.)2008;336(7634):2‐3. ">Forgacs 2008</a>). </p> <p>Inappropriate use of PPIs can contribute to polypharmacy, which is the use of multiple medications, specifically those that are not indicated. Polypharmacy may result in reduced medication adherence, falls, cognitive impairment, functional impairment, delirium, and hospitalization, all of which increase morbidity and mortality (<a href="./references#CD011969-bbs2-0109" title="GnjidicD , LeCouteurDG , KouladjianL , HilmerSN . Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clinics in Geriatric Medicine2012;28(2):237‐53. ">Gnjidic 2012</a>; <a href="./references#CD011969-bbs2-0116" title="HilmerSN , GnjidicD . The effects of polypharmacy in older adults. Clinical Pharmacology and Therapeutics2009;85(1):86‐8. ">Hilmer 2009</a>; <a href="./references#CD011969-bbs2-0117" title="IyerS , NaganathanV , McLachlanAJ , LeCouteurDG . Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs and Aging. New Zealand: Adis International Ltd, 2008; Vol. 25, issue 12:1021‐31. ">Iyer 2008</a>). The notion of deprescribing is becoming more relevant as clinicians begin to acknowledge the risks associated with polypharmacy (<a href="./references#CD011969-bbs2-0137" title="ScottIA , GrayLC , MartinJH , PillansPI , MitchellCA . Deciding when to stop: towards evidence‐based deprescribing of drugs in older populations. Evidence‐Based Medicine2013;18(4):121‐4. ">Scott 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011969-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011969-sec-0038"></div> <p>To determine the effects (benefits and harms) associated with deprescribing long‐term PPI therapy in adults, compared to chronic daily use (28 days or greater). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011969-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011969-sec-0039"></div> <section id="CD011969-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011969-sec-0041"> <h4 class="title">Types of studies</h4> <p>We included RCTs and quasi‐randomized trials. We applied no limitation on language or abstracts. </p> </section> <section id="CD011969-sec-0042"> <h4 class="title">Types of participants</h4> <p>Participants were adults (aged 18 years or greater) using a PPI chronically for one month (28 days) or greater. Participants also required an indication for PPI use: GERD (nonerosive reflux disease or GERD LA Grade A to D), functional dyspepsia, or undiagnosed dyspepsia. Participants were also considered eligible if they had a history PUD (bleeding or nonbleeding, or both), <i>H. pylori‐</i>positive or ‐negative diagnoses, recurrent peptic esophageal stricture or Barrett's esophagitis. Participants using a PPI as SUP or for gastroprotection in the setting of low‐dose acetylsalicylic acid (ASA) (less than 325 mg/day), anti‐inflammatory doses of NSAIDs, and steroids were eligible. We excluded trials if participants were taking high‐dose NSAIDs who require chronic PPI use for gastroprotection; however, those with occasional NSAID use were not excluded. </p> </section> <section id="CD011969-sec-0043"> <h4 class="title">Types of interventions</h4> <p>Included studies compared at least one of the deprescribing modalities with a control consisting of no change in continuous daily PPI use. Deprescribing was defined as one or more of the following interventions: </p> <p> <ol id="CD011969-list-0001"> <li> <p>Stopping PPI therapy: either via abrupt discontinuation or a tapering regimen.</p> </li> <li> <p>Step down: following abrupt discontinuation or tapering of PPI, an H<sub>2</sub>RA was prescribed (any H<sub>2</sub>RA at any approved dose and dosing interval per drug monograph). </p> </li> <li> <p>Reduction in PPI, which included the following subcategories:</p> <ol id="CD011969-list-0002"> <li> <p>intermittent PPI use as previously defined by the Canadian Consensus (<a href="./references#CD011969-bbs2-0094" title="ArmstrongD , MarshallJK , ChibaN , EnnsR , FalloneCA , FassR , et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults ‐ update 2004. Canadian Journal of Gastroenterology2005;19(1):15‐35. ">Armstrong 2005</a>); </p> </li> <li> <p>on‐demand PPI use as previously defined by the Canadian Consensus (<a href="./references#CD011969-bbs2-0094" title="ArmstrongD , MarshallJK , ChibaN , EnnsR , FalloneCA , FassR , et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults ‐ update 2004. Canadian Journal of Gastroenterology2005;19(1):15‐35. ">Armstrong 2005</a>); </p> </li> <li> <p>lower dose: continuous daily PPI therapy at a lower dose compared to a control arm within the trial. </p> </li> </ol> </li> <li> <p>Treatment of <i>H. pylori</i> (using any approved triple or quadruple therapy) followed by four to eight weeks of PPI maintenance therapy for bleeding or nonbleeding PUD and then PPI discontinuation. </p> </li> </ol> </p> <p>We excluded studies if treatment arms consisted of concomitant interventions such as rescue therapy (e.g. with antacids), lifestyle, diet modifications, or a combination of these. This did not affect inclusion if these additional interventions were handled similarly in all treatment arms. </p> </section> <section id="CD011969-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD011969-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011969-list-0003"> <li> <p>Lack of symptom control: reported as harms due to no change, recurring, worsening, new onset of at least one upper GI symptom (heartburn, regurgitation, dyspepsia, epigastric pain, nausea, bloating, belching). </p> </li> <li> <p>Drug burden/PPI use.</p> </li> <li> <p>Cost/resource use.</p> </li> </ol> </p> </section> <section id="CD011969-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011969-list-0004"> <li> <p>PDWE: included any positive outcome (e.g. improvement in cognition, improvement in vitamin B<sub>12</sub> levels, resolution of diarrhea) experienced as a result of the deprescribing intervention. </p> </li> <li> <p>ADWE: included all negative outcomes or adverse effects (e.g. GI bleeding, worsening endoscopic findings) occurring as a result of deprescribing with the exception of GI symptoms, which were measured separately. </p> </li> <li> <p>Participant satisfaction: positive or negative.</p> </li> </ol> </p> </section> </section> </section> <section id="CD011969-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We placed no restrictions on the language of publication.</p> <section id="CD011969-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ol id="CD011969-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 10) (<a href="./appendices#CD011969-sec-0106">Appendix 3</a>); </p> </li> <li> <p>MEDLINE (1946 to 15 November 2016) (<a href="./appendices#CD011969-sec-0107">Appendix 4</a>); </p> </li> <li> <p>Embase (1980 to 15 November 2016) (<a href="./appendices#CD011969-sec-0108">Appendix 5</a>); </p> </li> <li> <p>ClinicalTrials.gov;</p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP).</p> </li> </ol> </p> <p>As deprescribing is a new concept in the literature, we used a broad range of key words. Search terms for PPIs included both the generic and common brand names (<a href="./references#CD011969-bbs2-0103" title="DonnellanC , PrestonC , MoayyediP , SharmaN . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews2004, issue 4:CD003245. [DOI: 10.1002/14651858.CD003245.pub2] ">Donnellan 2004</a>; <a href="./references#CD011969-bbs2-0143" title="VanHerwaardenN , denBroederAA , JacobsW , van derMaasA , BijlsmaJWJ , vanVollenhovenRF , et al. Down‐titration and discontinuation strategies of tumor necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD010455.pub2] ">Van Herwaarden 2014</a>). A librarian from Cochrane reviewed the search strategy and a research librarian completed the search strategy (see <a href="./appendices#CD011969-sec-0106">Appendix 3</a>; <a href="./appendices#CD011969-sec-0107">Appendix 4</a>; <a href="./appendices#CD011969-sec-0108">Appendix 5</a>). Review authors will conduct future literature searches. </p> </section> <section id="CD011969-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of all primary studies and review articles.</p> </section> </section> <section id="CD011969-sec-0050"> <h3 class="title" id="CD011969-sec-0050">Data collection and analysis</h3> <p>We used predefined data extraction fields and data collection forms. We used Review Manager 5 for data analysis (<a href="./references#CD011969-bbs2-0136" title="The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For RCTs with dichotomous outcomes, we collected the number of outcome events and the total number of participants in treatment and control groups. </p> <section id="CD011969-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Three review authors (FJR, TB, and WT) independently reviewed search results, assessed study eligibility and trial quality, and extracted data. We resolved disagreements by discussion with another review author (CRF). The review authors retrieved and independently screened full‐text study reports and publications and identified studies for inclusion and identified/recorded reasons for exclusion of the ineligible studies. We made every attempt to exclude duplicates. We constructed a PRISMA flow diagram (<a href="#CD011969-fig-0001">Figure 1</a>) and a <a href="./references#CD011969-sec-0117" title="">Characteristics of excluded studies</a> table based on the information collected during this process. We used a standardized eligibility checklist. </p> <div class="figure" id="CD011969-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. NSAID: nonsteroidal anti‐inflammatory drug; PPI: proton pump inhibitor; RCT: randomized controlled trial." data-id="CD011969-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. NSAID: nonsteroidal anti‐inflammatory drug; PPI: proton pump inhibitor; RCT: randomized controlled trial. </p> </div> </div> </div> </section> <section id="CD011969-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>We used a standard data collection form for study characteristics and outcome data. Prior to data collection, two review authors independently completed a pilot eligibility and data extraction exercise to ensure criteria were consistently applied (<a href="./references#CD011969-bbs2-0115" title="Higgins JPT GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). Three review authors (FJR, TB, and WT) extracted the following study characteristics from included studies: </p> <p> <ol id="CD011969-list-0006"> <li> <p>methods: study design, total duration study and run in, number of study centers and location, study setting, withdrawals, date of study; </p> </li> <li> <p>participants: number, mean age, age range, gender, severity of condition, types of condition, inclusion criteria, and exclusion criteria; </p> </li> <li> <p>interventions: intervention, comparison, concomitant medications;</p> </li> <li> <p>outcomes: primary and secondary outcomes, time points reported;</p> </li> <li> <p>other: author contact information, funding for trial, notable conflicts of interest of trial authors. </p> </li> </ol> </p> <p>We resolved disagreements by discussion with a third review author (CRF). One review author (FJR) transferred the data into Review Manager 5 (<a href="./references#CD011969-bbs2-0136" title="The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014. ">RevMan 2014</a>). A second author (TB) reviewed data entry for accuracy. </p> </section> <section id="CD011969-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the quality and strength of the evidence using GRADE and study bias using Cochrane's tool for assessing risk of bias (<a href="./references#CD011969-bbs2-0115" title="Higgins JPT GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>Three review authors (FJR, TB, and WT) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011969-bbs2-0115" title="Higgins JPT GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements by discussion with a third review author (CRF). We ranked each potential source of bias as high, low, or unclear and provided a quote from the study to justify the bias grade (refer to <a href="./references#CD011969-sec-0116" title="">Characteristics of included studies</a> table for risk of bias assessments) using the following domains: </p> <p> <ol id="CD011969-list-0007"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <section id="CD011969-sec-0054"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>The review was conducted according to the published protocol and any deviation from the protocol is reported in the <a href="https://archie.cochrane.org/sections/documents/view?document=z1402061856093637941253753916025%26format=REVMAN#PRO_REV_DIFF" target="_blank">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD011969-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>We reported results as risk ratios (RR) where possible with 95% confidence intervals (CI). We pooled dichotomous data using a random‐effects model (<a href="./references#CD011969-bbs2-0102" title="DersimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">Dersimonian 1986</a>), and continuous outcomes using mean differences (MD) when outcomes were measured on the same scale. </p> </section> <section id="CD011969-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant undergoing PPI treatment. We conducted a scoping exercise prior to commencing the review and did not identify any cluster‐randomized trials for this comparison. As expected, we found no cluster‐randomized trials for this comparison after conducting comprehensive literature searching during the review. </p> </section> <section id="CD011969-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>During the data extraction process, we attempted to contact the primary author for clarification regarding missing or unclear data. No data were imputed. </p> </section> <section id="CD011969-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the Chi<sup>2</sup> statistic and I<sup>2</sup> statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (Chi<sup>2</sup> statistic with a P value less than 0.15 or I<sup>2</sup> statistic greater than 25%) via either statistic, we planned to explore this through prespecified subgroup analysis. Due to the paucity of included trials, we did not perform predefined subgroup analyses to investigate causes of heterogeneity. </p> </section> <section id="CD011969-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>We used the methods outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for assessment of bias (<a href="./references#CD011969-bbs2-0115" title="Higgins JPT GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). We attempted to contact study authors to request missing outcome data. Refer to <a href="./references#CD011969-sec-0116" title="">Characteristics of included studies</a> table for risk of bias assessment. </p> </section> <section id="CD011969-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 for analysis (<a href="https://archie.cochrane.org/sections/documents/view?document=z1402061856093637941253753916025%26format=REVMAN#REF-RevMan-2014" target="_blank">RevMan 2014</a>). We calculated 95% CIs for the treatment effect and used the Mantel‐Haenszel method for dichotomous data and the inverse variance method for continuous data. We used a random‐effects models for the analysis (<a href="https://archie.cochrane.org/sections/documents/view?document=z1402061856093637941253753916025%26format=REVMAN#REF-DerSimonian-1986" target="_blank">DerSimonian 1986</a>). </p> <section id="CD011969-sec-0061"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables based on the type of intervention (<a href="./full#CD011969-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011969-tbl-0002">summary of findings Table 2</a>)<i>.</i> We used the five GRADE considerations to assess the quality of evidence using methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011969-bbs2-0115" title="Higgins JPT GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>) and GRADEpro software (<a href="./references#CD011969-bbs2-0110" title="GRADE Working Group, McMaster University. GRADEpro. Version accessed 7 December 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro</a>). We justified all decisions to downgrade or upgrade the quality of studies by using footnotes, and we made comments to aid the reader's understanding of the review. We considered whether any additional outcome information was provided that we were unable to incorporate into meta‐analyses, and we planned to note this in the comments and state whether it supported or contradicted information derived from the meta‐analyses. </p> </section> </section> <section id="CD011969-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD011969-list-0008"> <li> <p>Deprescribing interventions (stopping PPI, lower‐dose PPI compared to control arm, on‐demand PPI, intermittent PPI, stopping PPI and changing to H<sub>2</sub>RA, treatment of <i>H. pylori</i> with four to eight weeks of PPI therapy). </p> </li> <li> <p>Diagnosis (GERD, esophagitis, functional dyspepsia, PUD, <i>H. pylori</i> infection). </p> </li> <li> <p>Trial setting (primary versus secondary care).</p> </li> <li> <p>Age (young adults versus older adults).</p> </li> </ol> </p> <p>We planned to assess the robustness of the conclusions based on the risk of bias assessments for blinding and allocation. We were unable to conduct subgroup analysis given the limited data. </p> </section> <section id="CD011969-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis defined a priori to assess the robustness of our conclusions by: outcome reporting and participant populations, and to assess any effect of risk of bias on our estimates. Data were too limited to perform sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011969-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011969-sec-0064"></div> <section id="CD011969-sec-0065"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD011969-sec-0116" title="">Characteristics of included studies</a>; <a href="./references#CD011969-sec-0117" title="">Characteristics of excluded studies</a> tables for details. </p> <section id="CD011969-sec-0066"> <h4 class="title">Results of the search</h4> <p>We identified 2357 references; 2317 through electronic searches of CENTRAL (Wiley), MEDLINE (OvidSP), and Embase (OvidSP), and 40 through other resources. We excluded 2268 clearly irrelevant references by reading the abstracts and retrieved 89 references for further detailed assessment. We excluded 83 references for the reasons listed in the <a href="https://archie.cochrane.org/sections/documents/view?document=z1402061856093637941253753916025%26format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES" target="_blank">Characteristics of excluded studies</a> table. Six references fulfilled the inclusion criteria (<a href="https://archie.cochrane.org/sections/documents/view?document=z1402061856093637941253753916025%26format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table). The results of the search are presented in <a href="#CD011969-fig-0001">Figure 1</a>. </p> </section> <section id="CD011969-sec-0067"> <h4 class="title">Included studies</h4> <p>We included six RCTs with 1753 participants (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>). The <a href="./references#CD011969-sec-0116" title="">Characteristics of included studies</a> table outlines details (e.g. sample size, participant characteristics, interventions, etc.) of all studies that met inclusion criteria. </p> <section id="CD011969-sec-0068"> <h5 class="title">Design</h5> <p>All six trials were RCTs. Four studies had an open‐label design while two were double‐blinded. To satisfy the inclusion criteria of chronic PPI usage (28 days or greater) with a control arm of no change in continuous daily PPI use, trials were required to have a run‐in phase of at least four weeks prior to randomization. For all trials, participants required symptom resolution at the end of the run‐in phase, prior to randomization. One trial went further and evaluated participants endoscopically at the beginning and end of the trial to assess the development of esophagitis (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>). Five trials explored on‐demand therapy and one trial investigated abrupt discontinuation (<a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>). Five studies had a duration of six months, while <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> conducted a trial of 13 weeks. </p> </section> <section id="CD011969-sec-0069"> <h5 class="title">Sample size</h5> <p>The included trials were relatively small (fewer than 500). A significant number of participants were excluded after the run‐in phases, as they did not achieve symptom resolution. <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> included the fewest participants after the run‐in phases (n = 105) and <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> had the largest trial (n = 598). </p> </section> <section id="CD011969-sec-0070"> <h5 class="title">Setting</h5> <p><a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> included participants from 23 Canadian sites. <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> had participants from 16 Italian centers. <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> included participants from 23 general practices from central and eastern regions of the Netherlands. The trial by <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a> included 41 French hospital sites (exact locations not disclosed). <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> included participants from 58 centers (29 in Germany, 12 in France, 11 in Switzerland, and six in Hungary). <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> included people from 61 sites (Austria, France, Germany, South Africa, and Spain). </p> </section> <section id="CD011969-sec-0071"> <h5 class="title">Participants</h5> <p>All participants were from the outpatient setting and had either NERD or milder grades of esophagitis (LA grade A or B). Participants also varied in age. one trial only included participants aged 65 years or greater (mean age 73 years) (<a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>), while the remaining trials included relatively younger participants (mean age 48 to 57 years). Four trials reported risk factors of alcohol and tobacco use (<a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>), and three trials indicated that heartburn was the major symptom experienced (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>). </p> </section> <section id="CD011969-sec-0072"> <h5 class="title">Interventions</h5> <p><a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> examined abrupt discontinuation and the remaining trials investigated on‐demand deprescribing. Three trials used pantoprazole 20 mg pills, two used rabeprazole 10 mg and 20 mg pills, and one used esomeprazole 20 mg pills. Duration of treatment was similar for five trials (six months or up to six months), while the remaining trial was conducted over 13 weeks (<a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>). </p> </section> <section id="CD011969-sec-0073"> <h5 class="title">Outcomes</h5> <p>Five studies defined primary outcomes; <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>; and <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> pertained to symptom control and relief and <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> reported volume of rescue medications as their primary outcome and symptom control, quality of life and final dose adjustment as secondary outcomes. <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> did not define primary outcomes. </p> </section> </section> <section id="CD011969-sec-0074"> <h4 class="title">Excluded studies</h4> <p>We excluded 83 studies. Three studies had the wrong study design (i.e. not RCTs) (<a href="./references#CD011969-bbs2-0015" title="BautistaJM . The rising trend of on‐demand and intermittent proton pump inhibitor therapy in gastroesophageal reflux disease: what is the evidence?. Journal of Gastroenterology and Hepatology2006;21(Suppl 5):S112‐4. ">Bautista 2006</a>; <a href="./references#CD011969-bbs2-0044" title="InadomiJM , JamalR , MurataGH , HoffmanRM , LavezoLA , VigilJM , et al. Step‐down management of gastroesophageal reflux disease. Gastroenterology2001;121(5):1095‐100. ">Inadomi 2001</a>; <a href="./references#CD011969-bbs2-0065" title="PonceJ , ArgüelloL , BastidaG , PonceM , OrtizV , GarriguesV . On‐demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health‐related quality of life, and patient satisfaction. Digestive Diseases and Sciences2004;49(6):931‐6. ">Ponce 2004</a>). Six studies included chronic NSAID users (<a href="./references#CD011969-bbs2-0007" title="AnnibaleB , FranceschiM , FusilloM , BeniM , CesanaB , Delle FaveG . Omeprazole in patient with mild or moderate reflux esophagitis induces lower relapse rates than ranitidine during maintenance treatment. Hepato‐Gastroenterology1998;45(21):742‐51. ">Annibale 1998</a>; <a href="./references#CD011969-bbs2-0014" title="BateCM , GreenJR , AxonAT , MurrayFE , TildesleyG , EmmasCE , et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro‐oesophageal reflux disease‐associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Alimentary Pharmacology &amp; Therapeutics1997;11(4):755‐63. ">Bate 1997</a>; <a href="./references#CD011969-bbs2-0025" title="DentJ , YeomansND , MackinnonM , ReedW , NarielvalaFM , HetzelDJ , et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut1994;35(5):590‐8. ">Dent 1994</a>; <a href="./references#CD011969-bbs2-0036" title="GoughAL , LongRG , CooperBT , FostersCS , GarrettAD , LangworthyCH . Lansoprazole versus ranitidine in the maintenance treatment reflux oesophagitis. Alimentary Pharmacology &amp; Therapeutics1996;10(4):529‐39. ">Gough 1996</a>; <a href="./references#CD011969-bbs2-0037" title="HatlebakkJG , BerstadA . Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Alimentary Pharmacology &amp; Therapeutics1997;11(2):365‐72. ">Hatlebakk 1997a</a>; <a href="./references#CD011969-bbs2-0038" title="HatlebakkJG , BerstadA . Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Alimentary Pharmacology &amp; Therapeutics1997;11(6):1093‐9. ">Hatlebakk 1997b</a>). In one study, participants did not have an indication for PPI use (i.e. healthy volunteers) (<a href="./references#CD011969-bbs2-0061" title="NiklassonA , LindströmL , SimrénM , LindbergG , BjörnssonE . Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double‐blind placebo‐controlled trial. American Journal of Gastroenterology2010;105(7):1531‐7. ">Niklasson 2010</a>). Seventy‐three studies did not have a control arm (i.e. no continuous/no change in chronic PPI use) (<a href="./references#CD011969-bbs2-0008" title="ArchambaultAP , PareP , BaileyRJ , NavertH , WilliamsCN , FreemanHJ . Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. Gastroenterology1988;94(5 Pt 1):1130‐4. ">Archambault 1988</a>; <a href="./references#CD011969-bbs2-0009" title="BardhanKD . Omeprazole or ranitidine for reflux oesophagitis: comment. National Medical Journal of India1990;3(1):20‐1. ">Bardhan 1990</a>; <a href="./references#CD011969-bbs2-0010" title="BardhanKD , HawkeyCJ , LongRG , MorganAG , WormsleyKG , MoulesIK , et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Alimentary Pharmacology &amp; Therapeutics1995;9(2):145‐51. ">Bardhan 1995</a>; <a href="./references#CD011969-bbs2-0011" title="BateCM , WilkinsonSP , BradbyGV , BatesonMC , HislopWS , CroweJP , et al. Randomized, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut1989;30(10):1323‐8. ">Bate 1989</a>; <a href="./references#CD011969-bbs2-0012" title="BateCM , KeelingPW , O'MorainC , WilkinsonSP , FosterDN , MountfordRA , et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic and histological evaluations. Gut1990;31(9):968‐72. ">Bate 1990</a>; <a href="./references#CD011969-bbs2-0013" title="BateCM , BoothSN , CroweJP , MountfordRA , KeelingPW , Hepworth‐JonesB , et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut1995;36(4):492‐8. ">Bate 1995</a>; <a href="./references#CD011969-bbs2-0016" title="BayerdörfferE , MannesGA , SommerA , HöchterW , WeingartJ , HatzR , et al. Long‐term follow‐up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scandinavian Journal of Gastroenterology1992;28(196):19‐25. ">Bayerdörffer 1993</a>; <a href="./references#CD011969-bbs2-0017" title="BigardMA , GenestinE . Treatment of patients with heartburn without endoscopic evaluation: on‐demand treatment after effective continuous administration of lansoprazole 15 mg. Alimentary Pharmacology &amp; Therapeutics2005;22(7):635‐43. ">Bigard 2005</a>; <a href="./references#CD011969-bbs2-0018" title="BjörnssonE , AbrahamssonH , SimrénM , MattssonN , JensenC , AgerforzP , et al. Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trial. Alimentary Pharmacology &amp; Therapeutics2006;24(6):945‐54. ">Björnsson 2006</a>; <a href="./references#CD011969-bbs2-0019" title="BytzerP , BlumA , DeHerdtD , DuboisD . Six‐month trial of on‐demand rabeprazole 10 mg maintains symptom relief in patients with non‐erosive reflux disease. Alimentary Pharmacology &amp; Therapeutics2004;20(2):181‐8. ">Bytzer 2004</a>; <a href="./references#CD011969-bbs2-0020" title="CarlssonR , DentJ , WattsR , RileyS , SheikhR , HatlebakkJ , et al. Gastro‐oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. European Journal of Gastroenterology &amp; Hepatology1998;10(2):119‐24. ">Carlsson 1998</a>; <a href="./references#CD011969-bbs2-0021" title="ChenSP , BeiL , WenSH . Study on omeprazole 20 mg twice weekly in prevention of duodenal ulcer relapse. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]1993;32(8):538‐41. ">Chen 1993</a>; <a href="./references#CD011969-bbs2-0022" title="DabholkarAH , HanC , ParisMM , PerezMC , AtkinsonSN , PeuraDA . The 12‐month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro‐oesophageal reflux disease. Alimentary Pharmacology &amp; Therapeutics2011;33(3):366‐77. ">Dabholkar 2011</a>; <a href="./references#CD011969-bbs2-0023" title="DeboeverG , WagnerC , BourgeoisN , MulsV , BelaicheJ , AzeradM‐A , et al. Lansoprazole 15 mg OD is superior to ranitidine 300 mg OD in relieving heartburn and healing patients with (endoscopically confirmed) reflux oesophagitis grade I [Le lansoprazole 15 mg OD est superieur a la ranitidine 300 mg OD dans le soulagement du pyrosis et pour guerison des patient souffrant d'oesophagite de reflux de grade I (confirme par endoscopie)]. Acta Endoscopica2003;33(4):573‐85. ">Deboever 2003</a>; <a href="./references#CD011969-bbs2-0024" title="DentJ , HetzelDJ , MackinnonMA , ReedWD , NarielvalaFM . Evaluation of omeprazole in reflux oesophagitis. Scandinavian Journal of Gastroenterology1989;24(166):76‐82. ">Dent 1989</a>; <a href="./references#CD011969-bbs2-0026" title="DeVaultKR , JohansonJF , JohnsonDA , LiuS , SostekMB . Maintenance of healed erosive esophagitis: a randomized six‐month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clinical Gastroenterology and Hepatology2006;4(7):852‐9. ">DeVault 2006</a>; <a href="./references#CD011969-bbs2-0027" title="EarnestDL , DorschE , JonesJ , JenningsDE , Greski‐RosePA . A placebo‐controlled dose‐ranging study of lansoprazole in the management of reflux esophagitis. American Journal of Gastroenterology1998;93(2):238‐43. ">Earnest 1998</a>; <a href="./references#CD011969-bbs2-0028" title="EgglestonA , KatelarisPH , NandurkarS , ThorpeP , HoltmannG . Clinical trial: the treatment of gastro‐oesophageal reflux disease in primary care ‐ prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Alimentary Pharmacology &amp; Therapeutics2009;29(9):967‐78. ">Eggleston 2009</a>; <a href="./references#CD011969-bbs2-0029" title="EscourrouJ , DeprezP , SaggioroA , GeldofH , FischerR , MaierC . Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Alimentary Pharmacology &amp; Therapeutics1999;13(11):1481‐91. ">Escourrou 1999</a>; <a href="./references#CD011969-bbs2-0030" title="FarleyA , WrubleLD , HumphriesTJ . Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double‐blind, randomized clinical trial. American Journal of Gastroenterology2000;95(8):1894‐9. ">Farley 2000</a>; <a href="./references#CD011969-bbs2-0031" title="FassR , JohnsonDA , OrrWC , HanC , ModyR , SternKN , et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD‐related sleep disturbances in patients with symptomatic GERD. American Journal of Gastroenterology2011;106(3):421‐31. ">Fass 2011</a>; <a href="./references#CD011969-bbs2-0032" title="FassR , InadomiJ , HanC , ModyR , O'NeilJ , PerezMC . Maintenance of heartburn relief after step‐down from twice‐daily proton pump inhibitor to once‐daily dexlansoprazole modified release. Clinical Gastroenterology and Hepatology2012;10(3):247‐53. ">Fass 2012</a>; <a href="./references#CD011969-bbs2-0033" title="FennertyMB , PeuraDA , RiffDS , SnoddyAM . Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self‐treating subjects. Alimentary Pharmacology &amp; Therapeutics2009;30(5):459‐68. ">Fennerty 2009</a>; <a href="./references#CD011969-bbs2-0034" title="GohKL , BoonyapisitS , LaiKH , ChangR , KangJY , LamSK . Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: a randomized double‐blind, placebo‐controlled study. Journal of Gastroenterology and Hepatology1995;10(1):92‐7. ">Goh 1995</a>; <a href="./references#CD011969-bbs2-0035" title="GohKL , BenamouzigR , SanderP , SchwanT . Efficacy of pantoprazole 20mg daily compared with esomeprazole 20mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double‐blind comparative trial ‐ the EMANCIPATE study. European Journal of Gastroenterology &amp; Hepatology2007;19(3):205‐11. ">Goh 2007</a>; <a href="./references#CD011969-bbs2-0039" title="HavelundT , LaursenLS , Skoubo‐KristensenE , AndersenBN , PedersenSA , JensenKB , et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. BMJ1988;296(6515):89‐92. ">Havelund 1988</a>; <a href="./references#CD011969-bbs2-0040" title="HoshinoE , UmedaN , SanoJ , MikiK , YahagiN , OkaM , et al. Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full‐dose or everyday half‐dose administration?. Journal of Clinical Gastroenterology1995;20(Suppl 2):S72‐4. ">Hoshino 1995</a>; <a href="./references#CD011969-bbs2-0041" title="HowdenCW , HenningJM , HuangB , LukasikN , FrestonJW . Management of heartburn in a large, randomized, community‐based study: comparison of four therapeutic strategies. American Journal of Gastroenterology2001;96(6):1704‐10. ">Howden 2001</a>; <a href="./references#CD011969-bbs2-0042" title="HowdenCW , LarsenLM , PerezMC , PalmerR , AtkinsonSN . Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis ‐ maintenance of healing and symptom relief. Alimentary Pharmacology &amp; Therapeutics2009;30(9):895‐907. ">Howden 2009</a>; <a href="./references#CD011969-bbs2-0043" title="HsuPI , LuCL , WuDC , KuoCH , KaoSS , ChangCC , et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. Clinical Gastroenterology and Hepatology2015;13(5):859‐66. ">Hsu 2015</a>; <a href="./references#CD011969-bbs2-0045" title="InadomiJM , McIntyreL , BernardL , FendrickAM . Step‐down from multiple‐ to single‐dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPI. American Journal of Gastroenterology2003;98(9):1940‐4. ">Inadomi 2003</a>; <a href="./references#CD011969-bbs2-0046" title="JamesOF , Parry‐BillingsKS . Comparison of omeprazole and histamine H2‐receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis. Age and Ageing1994;23(2):121‐6. ">James 1994</a>; <a href="./references#CD011969-bbs2-0047" title="JohnsonDA , BenjaminSB , VakilNB , GoldsteinJL , LametM , WhippleJ , et al. Esomeprazole once daily for 6 months Is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double‐blind, placebo‐controlled study of efficacy and safety. American Journal of Gastroenterology2001;96(1):27‐34. ">Johnson 2001</a>; <a href="./references#CD011969-bbs2-0048" title="JohnsonD , CrawleyJA , HwangC , KrownB . Clinical trial: esomeprazole for moderate‐to‐severe nighttime heartburn and gastro‐oesophageal reflux disease‐related sleep disturbances. Alimentary Pharmacology &amp; Therapeutics2010;32(2):182‐90. ">Johnson 2010</a>; <a href="./references#CD011969-bbs2-0049" title="JonesRH , BaxterG . Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid‐related dyspepsia in general practice. Alimentary Pharmacology &amp; Therapeutics1997;11(3):541‐6. ">Jones 1997</a>; <a href="./references#CD011969-bbs2-0050" title="Juul‐HansenP , RydningA . On‐demand requirements of patients with endoscopy‐negative gastro‐oesophageal reflux disease: H2‐blocker vs. proton pump inhibitor. Alimentary Pharmacology &amp; Therapeutics2008;29(2):207‐12. ">Juul‐Hansen 2008</a>; <a href="./references#CD011969-bbs2-0051" title="Kaplan‐MachlisB , SpieglerGE , ZodetMW , RevickiDA . Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Archives of Family Medicine2000;9(7):624‐30. ">Kaplan‐Machlis 2000</a>; <a href="./references#CD011969-bbs2-0052" title="KaspariS , KupcinskasL , HeinzeH , BerghöferP . Pantoprazole 20 mg on demand is effective in the long‐term management of patients with mild gastro‐oesophageal reflux disease. European Journal of Gastroenterology &amp; Hepatology2005;17(9):935‐41. ">Kaspari 2005</a>; <a href="./references#CD011969-bbs2-0053" title="Klinkenberg‐KnolEC , JansenJM , FestenHP , MeuwissenSG , LamersCB . Double‐blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet1987;1(8529):349‐51. ">Klinkenberg‐Knol 1987</a>; <a href="./references#CD011969-bbs2-0054" title="KovacsTO , FrestonJW , HaberMM , AtkinsonS , HuntB , PeuraDA . Long‐term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. Digestive Diseases and Sciences2010;55(5):1325‐36. ">Kovacs 2010</a>; <a href="./references#CD011969-bbs2-0055" title="LabenzJ , ArmstrongD , LauritsenK , KatelarisP , SchmidtS , SchützeK , et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Alimentary Pharmacology &amp; Therapeutics2005;22(9):803‐11. ">Labenz 2005</a>; <a href="./references#CD011969-bbs2-0056" title="LauritsenK , DevièreJ , BigardMA , BayerdörfferE , MózsikG , MurrayF , et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Alimentary Pharmacology &amp; Therapeutics2003;17(3):331‐41. ">Lauristen 2003</a>; <a href="./references#CD011969-bbs2-0057" title="LindT , HavelundT , LundellL , GliseH , LauritsenK , PedersenSA , et al. On demand therapy with omeprazole for the long‐term management of patients with heartburn without oesophagitis ‐ a placebo‐controlled randomized trial. Alimentary Pharmacology &amp; Therapeutics1999;13(7):907‐14. ">Lind 1999</a>; <a href="./references#CD011969-bbs2-0058" title="LundellL , BackmanL , EkströmP , EnanderLK , FalkmerS , FausaO , et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scandinavian Journal of Gastroenterology1991;26(3):248‐56. ">Lundell 1991</a>; <a href="./references#CD011969-bbs2-0059" title="MetzDC , BochenekWJ . Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Alimentary Pharmacology &amp; Therapeutics2003;17(1):155‐64. ">Metz 2003</a>; <a href="./references#CD011969-bbs2-0060" title="NagaharaA , HojoM , AsaokaD , SasakiH , WatanabeS . A randomized prospective study comparing the efficacy of on‐demand therapy versus continuous therapy for 6 months for long‐term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan. Scandinavian Journal of Gastroenterology2014;49(4):409‐17. ">Nagahara 2014</a>; <a href="./references#CD011969-bbs2-0062" title="Norman HansenA , BergheimR , FagertunH , LundH , MoumB . A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. International Journal of Clinical Practice2005;59(6):665‐71. ">Norman Hansen 2005</a>; <a href="./references#CD011969-bbs2-0063" title="PeuraDA , RiffDS , SnoddyAM , FennertyMB . Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self‐treating subjects. Alimentary Pharmacology &amp; Therapeutics2009;30(5):459‐68. ">Peura 2009</a>; <a href="./references#CD011969-bbs2-0064" title="PeuraD , LeMoigneA , PollackC , NagyP , LindT . A 14‐day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction. Postgraduate Medical Journal2016;128(6):577‐83. ">Peura 2016</a>; <a href="./references#CD011969-bbs2-0066" title="ReimerC , BytzerP . Discontinuation of long‐term proton pump inhibitor therapy in primary care patients: a randomized placebo‐controlled trial in patients with symptom relapse. European Journal of Gastroenterology &amp; Hepatology2010;22(10):1182‐8. ">Reimer 2010</a>; <a href="./references#CD011969-bbs2-0067" title="RichterJE , BochenekW . Oral pantoprazole for erosive esophagitis: a placebo‐controlled, randomized clinical trial. American Journal of Gastroenterology2000;95(11):3071‐80. ">Richter 2000</a>; <a href="./references#CD011969-bbs2-0068" title="RichterJE , FragaP , MackM , SabesinSM , BochenekW . Prevention of erosive oesophagitis relapse with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2004;20(5):567‐75. ">Richter 2004</a>; <a href="./references#CD011969-bbs2-0069" title="RobinsonM , SahbaB , AvnerD , JhalaN , Greski‐RosePA , JenningsDE . A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Alimentary Pharmacology &amp; Therapeutics1995;9(1):25‐30. ">Robinson 1995</a>; <a href="./references#CD011969-bbs2-0070" title="SandmarkS , CarlssonR , FausaO , LundellL . Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double‐blind, randomized, Scandinavian multicenter study. Scandinavian Journal of Gastroenterology1988;23(5):625‐32. ">Sandmark 1988</a>; <a href="./references#CD011969-bbs2-0071" title="ScholtenT , DekkersCP , SchützeK , KörnerT , BohuschkeM , GatzG . On‐demand therapy with pantoprazole 20 mg as effective long‐term management of reflux disease in patients with mild GERD: the ORION trial. Digestion2005;72(2‐3):76‐85. ">Scholten 2005</a>; <a href="./references#CD011969-bbs2-0072" title="SjöstedtS , BefritsR , SylvanA , HarthonC , JörgensenL , CarlingL , et al. Daily treatment with esomeprazole is superior to that taken on‐demand for maintenance of healed erosive oesophagitis. Alimentary Pharmacology &amp; Therapeutics2005;22(3):183‐91. ">Sjöstedt 2005</a>; <a href="./references#CD011969-bbs2-0073" title="SontagSJ , RobinsonM , RoufailW , HirschowitzBI , SabesinSM , WuWC , et al. Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi‐centre double‐blind study. Alimentary Pharmacology &amp; Therapeutics1997;11(2):373‐80. ">Sontag 1997</a>; <a href="./references#CD011969-bbs2-0074" title="SunJ , YuanYZ , HouXH , ZouDW , LuB , ChenMH , et al. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis. World Journal of Gastroenterology2015;21(22):6965‐73. ">Sun 2015</a>; <a href="./references#CD011969-bbs2-0075" title="TalleyNJ , LauritsenK , Tunturi‐HihnalaH , LindT , MoumB , BangC , et al. Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of 'on‐demand' therapy for 6 months. Alimentary Pharmacology &amp; Therapeutics2001;15(3):347‐54. ">Talley 2001</a>; <a href="./references#CD011969-bbs2-0076" title="TalleyN , MooreM , SprogisA , KatelarisP . Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Medical Journal of Australia2002;117:415‐9. ">Talley 2002a</a>; <a href="./references#CD011969-bbs2-0077" title="TalleyNJ , VenablesTL , GreenJR , ArmstrongD , O'KaneKP , GiafferM , et al. Esomeprazole 40 mg and 20 mg is efficacious in the long term management of patients with endoscopy‐negative gastro‐oesophageal reflux disease: a placebo‐controlled trial of on‐demand therapy for 6 months. European Journal of Gastroenterology &amp; Hepatology2002;14(8):857‐63. ">Talley 2002b</a>; <a href="./references#CD011969-bbs2-0078" title="TanVP , WongWM , CheungTK , LaiKC , HungIF , ChanP , et al. Treatment of non‐erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. Journal of Gastroenterology2011;46(7):906‐12. ">Tan 2011</a>; <a href="./references#CD011969-bbs2-0079" title="TsaiHH , ChapmanR , ShepherdA , McKeithD , AndersonM , VearerD , et al. Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study. Alimentary Pharmacology &amp; Therapeutics2004;20(6):657‐65. ">Tsai 2004</a>; <a href="./references#CD011969-bbs2-0080" title="VakilNB , ShakerR , JohnsonDA , KovacsT , BaergRD , HwangC , et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6‐month, randomized, double‐blind, placebo‐controlled study of efficacy and safety. Alimentary Pharmacology &amp; Therapeutics2001;15:927‐35. ">Vakil 2001</a>; <a href="./references#CD011969-bbs2-0081" title="ValenzuelaJ , BerlinR , SnapeW , JohnsonT , HirschowitzB , Colon‐PaganJ , et al. U.S. experience with omeprazole in duodenal ulcer‐multicenter double‐blind comparative study with ranitidine. Digestive Diseases and Sciences1991;36(6):761‐8. ">Valenzuela 1991</a>; <a href="./references#CD011969-bbs2-0082" title="VanRensburgCJ , HoniballPJ , GrundlingHD , vanZylJH , SpiesSK , EloffFP , et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux esophagitis. Alimentary Pharmacology &amp; Therapeutics1996;10(3):397‐401. ">Van Rensburg 1996</a>; <a href="./references#CD011969-bbs2-0083" title="VanRensburgC , BerghöferP , EnnsR , DattaniID , MaritzJF , Gonzalez CarroP , et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer‐like functional dyspepsia. Current Medical Research and Opinion2008;24(7):2009‐18. ">Van Rensburg 2008</a>; <a href="./references#CD011969-bbs2-0084" title="VantrappenG , RutgeertsL , SchurmansP , CoenegrachtsJL . Omeprazole (40 mg) is superior to ranitidine in short‐term treatment of ulcerative reflux esophagitis. Digestive Diseases and Sciences1988;33(5):523‐9. ">Vantrappen 1988</a>; <a href="./references#CD011969-bbs2-0085" title="VanZylJH , deK Grundling H , vanRensburgCJ , RetiefFJ , O'KeefeSJ , TheronI , et al. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux‐oesophagitis: a randomized, double‐blind, parallel, and multicentre study. European Journal of Gastroenterology &amp; Hepatology2000;12(2):197‐202. ">Van Zyl 2000</a>; <a href="./references#CD011969-bbs2-0086" title="VenablesT , NewlandR , PatelA , HoleJ , WilcockC , TurbittM . Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro‐oesophageal reflux disease in general practice. Scandinavian Journal of Gastroenterology1997;32:965‐73. ">Venables 1997</a>; <a href="./references#CD011969-bbs2-0087" title="VigneriS , TerminiR , LeandroG , BadalamentiS , PantalenaM , SavarinoV , et al. A comparison of five maintenance therapies for reflux esophagitis. New England Journal of Medicine1995;333(17):1106‐10. ">Vigneri 1995</a>; <a href="./references#CD011969-bbs2-0088" title="Danish Omeprazole Study Group. Omeprazole and cimetidine in the treatment of ulcers of the body of the stomach: a double blind comparative trial. BMJ1989;298(6674):645‐7. ">Wulff 1989</a>; <a href="./references#CD011969-bbs2-0089" title="ZwislerJE , JarbolDE , LassenAT , KragstrupJ , ThorsgaardN , Schaffalitzky de MuckadellOB . Placebo‐controlled discontinuation of long‐term acid‐suppressant therapy: a randomised trial in general practice. International Journal of Family Medicine2015; Vol. 2015:175436. [DOI: 10.1155/2015/175436] ">Zwisler 2015</a>). Refer to <a href="./references#CD011969-sec-0117" title="">Characteristics of excluded studies</a> table for deprescribing trials that did not meet all inclusion criteria. </p> </section> </section> <section id="CD011969-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD011969-sec-0116" title="">Characteristics of included studies</a> table for study details including all aspects of risk of bias. <a href="#CD011969-fig-0002">Figure 2</a> and <a href="#CD011969-fig-0003">Figure 3</a> provide a visual summary of the risk of bias in included studies presented as percentages across all included studies and for individual studies. </p> <div class="figure" id="CD011969-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD011969-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011969-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD011969-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011969-sec-0076"> <h4 class="title">Allocation</h4> <p>Contribution of allocation bias was difficult to determine, as four trials did not describe how they performed allocation (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>). The remaining two trials used sound methods: <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> used sealed boxes containing study medication, and participants were allocated according to the numbering in ascending order, while <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> used a computer‐generated list, enlisted an external party to generate sealed identical containers which were sent to the general practitioners, and participants were allocated the next available number of the set on entry into the trial. </p> </section> <section id="CD011969-sec-0077"> <h4 class="title">Blinding</h4> <p>Of the six trials included, two trials were double blinded (<a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>), although the authors of van der Velden and colleagues noted that the data were analyzed unblinded. <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> blinded participants by providing identical containers and by providing the control arm with daily dose of PPI plus placebo rescue medication to use as needed and providing the inverse to the intervention group (placebo daily plus PPI when needed). <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> did not comment how blinding was maintained and whether pills looked identical in both arms. The remaining four trials had an open‐label design (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>). Many of the outcomes related to symptom relief, despite use of scales, relied on subjective reporting, and thus were subject to bias. For example, <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a> evaluated participant‐rated symptom relief (primary outcome) using a Likert scale and it was unclear if investigators saw participant satisfaction measures before they assessed satisfaction. <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> also measured subjective outcomes (symptom control and satisfaction/unwillingness to continue), creating high risk of bias. However, the objective measure of pill count was unbiased (measurement was not likely to be influenced by lack of blinding). Participant‐rated effect of treatment and satisfaction in the trial by <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> were also inherently subject to bias as neither participants nor assessors were blinded. </p> </section> <section id="CD011969-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>Reporting of outcome data revealed a relatively high risk of bias as the majority of trials had participants lost to follow‐up or did not report on all predefined outcomes, or both. </p> <p>Although the study completion rate was high for <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a> (greater than 80%), the reason for dropout was unclear in all instances and there was a statistically significant higher number of participants who withdrew from the trial for reasons unknown, defined as 'other' in the on‐demand treatment group. Only 67/81 participants were analyzed for pill usage in the continuous treatment group, and only 55/71 for the on‐demand treatment group, with no explanation provided. </p> <p><a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> had a relatively higher dropout rate (22%) but maintained sufficient participation to achieve their power calculation. Although they did not report if characteristics differed between those who stayed in study, versus those who were excluded, the unwillingness to continue as cause of dropout was similar between groups (6% versus 8%) for the long‐term phase. </p> <p><a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> and <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> reported overall dropout rates making it difficult to assess if reasons for withdrawal from the study were similar between treatment and control groups. Endpoints in the <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> trial were not clearly defined, also making it difficult to assess completion of outcome data reporting. <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> clearly reported dropouts and reasons, however did not comment on whether differences were significant between groups (33% dropout in the on‐demand arm, which was greater than the 20% anticipated). The authors of this study stated that 40 participants were required in each arm (<a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> page 44), though a power calculation was not described. <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a> arbitrarily set a fixed sample size of 200, with no discussion of power or adequate sample size. In total, three of the five trials did not report a power calculation, therefore it is unclear how significant these dropout rates were (<a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>). <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> presented a comprehensive review in their figure two, regarding dropout rates including reasons within in each study arm. </p> </section> <section id="CD011969-sec-0079"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> appeared to have significant reporting bias for several outcomes because of incomplete reporting of results. Number of rescue pills used weekly was not reported as absolute numbers, but rather participants were divided into groups based on usage that were not defined a‐priori (less than two pills, two to five pills, and six or seven pills weekly). The authors did not predefine how they would assess participant satisfaction. Predefined secondary outcomes of symptom control and quality of life were not assessed separately and rather inferred from results of two surveys (Quality of Life in Reflux and Dyspepsia (QolRad), and SF‐36 Health Survey). The use of a modified per protocol population lead to results that were more difficult to interpret, and additionally, standard deviations (SD) were not reported for all their predefined outcomes. </p> <p>There was significant bias in the <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> trial, as outcomes were not predefined in their methods and event rates were not reported. Despite methods suggesting that investigators classified symptom severity as mild, moderate, or severe, symptom assessment was only reported as percentage of participants with symptoms. Baseline participant demographics/characteristics were presented as overall numbers rather than for each group, so it is unknown if groups were balanced at randomization and if risk factors in one arm outweighed the other. </p> <p>Three trials reported all predefined outcomes (<a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>). However, <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> combined satisfaction ratings in their results, which was not predefined (e.g. reported results as a combination of 'good' or 'very good' ratings and 'satisfied' or 'very satisfied' ratings). This trial did not report SDs for pill usage. We were unable to use participant satisfaction scale in the meta‐analysis as SDs were not reported for this scale. </p> <p><a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a> reported additional analysis, but acknowledged the change to their protocol, to include statistical analysis rather than just descriptive data (e.g. subanalysis of relapse rates in different levels of on‐demand use). <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> presented comprehensive tables and figures and included means, SDs, event numbers, absolute differences calculated, P values, and CIs. <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> reported additional data in the results section although they were not predefined in their study design (e.g. tolerability, number of pills used). <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> addressed all outcomes and reported data for both primary and secondary outcomes. </p> </section> <section id="CD011969-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>The use of perceived mean daily symptom load (MDSL) score by <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> could contribute to bias, as this scale was defined by the authors, was not validated, and psychometric properties were unknown. Evaluating bias for the trial published by <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> was challenging as insufficient data were provided to make an accurate assessment. </p> <p>Five of the six trials listed drug manufacturers as external funding sources: <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a> by Janssen‐Cilag; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> by Janssen‐Ortho; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> by Pharmacia, Milano, Italy; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> by Nycomed BV; and <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> by AstraZeneca. Their role was unclear/unreported in four trials (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>), while <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> explicitly stated drug manufacturer was not involved in any aspect of participant selection, data collection, analysis, interpretation, writing and submission of manuscript. <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> did not list sources of funding. </p> </section> </section> <section id="CD011969-sec-0081"> <h3 class="title" id="CD011969-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD011969-tbl-0001"><b>Summary of findings for the main comparison</b> On‐demand deprescribing compared to continued use for people with moderate GERD and mild esophagitis</a>; <a href="./full#CD011969-tbl-0002"><b>Summary of findings 2</b> Abrupt discontinuation deprescribing compared to continued use for people with mild‐to‐moderate esophagitis</a> </p> <section id="CD011969-sec-0082"> <h4 class="title">Primary outcomes</h4> <section id="CD011969-sec-0083"> <h5 class="title">Lack of symptom control</h5> <p>All six studies measured lack of symptom control and they analyzed data separately based on the deprescribing interventions (i.e. (on‐demand therapy) and abrupt discontinuation). <a href="./references#CD011969-fig-0004" title="">Analysis 1.1</a> summarizes the pooled outcomes (n = 1653) for on‐demand deprescribing versus continuous PPI therapy under the heading of 'Lack of symptom control'. Lack of symptom control was defined as either treatment failure (i.e. return of symptoms) or inadequate symptom relief. Two trials assessed treatment failure (<a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>). In <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>, treatment failure was the inverse of rate of symptom relief. In <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>, symptom recurrence was interpreted as treatment failure. Three trials assessed inadequate relief (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>). <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a> and <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> reported dropout rates secondary to inadequate relief. <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a> reported effect of the study medication on heartburn control as 'good' or 'very good'. The remaining participants were interpreted as having inadequate symptom relief. Intention‐to‐treat (ITT) was used to report event rates, Overall, 16.3% of participants in the on‐demand deprescribing group experienced lack of symptom control versus 9.2% in continuous treatment (RR 1.71, 95% CI 1.31 to 2.21). </p> <p><a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> reported the percentage of participants with return of GI reflux symptoms (i.e. lack of symptom control)<i>.</i> The data from this trial were evaluated separately as the deprescribing intervention was stopping PPI (i.e. abrupt discontinuation). From this value, the event rate was extrapolated using ITT (<a href="./references#CD011969-fig-0008" title="">Analysis 2.1</a>). Similarly to on‐demand therapy, abrupt discontinuation was associated with an increased risk in return of GI symptoms. Given that only a single abrupt discontinuation trial reported data for this outcome, firm conclusions cannot be made. </p> </section> <section id="CD011969-sec-0084"> <h5 class="title">Drug burden/proton pump inhibitor use</h5> <p>Three studies (n = 1152) evaluated the number of pills used throughout the duration of each trial (<a href="./references#CD011969-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>). A fourth trial, <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>, reported weekly "rescue" pill use rather than total weekly PPI use. We did not include PPI use data from this trial as there was insufficient reporting of the outcome to allow for inclusion in meta‐analysis. </p> <p>All three trials included in the analysis reported mean number of pills used per day (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>). For the purpose of this review, the mean values along with their SD were converted to weekly PPI consumption. Reported means and SDs were multiplied by a factor of seven to convert to total PPI use per week. The overall effect was a mean reduction of PPI use by 3.79 pills per week 95% CI ‐4.73 to ‐2.84 (P &lt; 0.00001). There was significant heterogeneity (I<sup>2</sup> greater than 96%). </p> </section> <section id="CD011969-sec-0085"> <h5 class="title">Cost/resource use</h5> <p>We were unable to perform analyses of cost or resource use because the studies did not report this information. </p> </section> </section> <section id="CD011969-sec-0086"> <h4 class="title">Secondary outcomes</h4> <section id="CD011969-sec-0087"> <h5 class="title">Positive drug withdrawal events</h5> <p>We were unable to perform analyses of PDWEs because the studies did not report this information. </p> </section> <section id="CD011969-sec-0088"> <h5 class="title">Adverse drug withdrawal events</h5> <p>Two trials reported ADWEs; one trial had on‐demand deprescribing (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>) and the other abrupt discontinuation (<a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>). <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> reported 15 participants developing esophagitis in the on‐demand arm while those who continued with daily PPI use did not develop esophagitis (<a href="./references#CD011969-fig-0006" title="">Analysis 1.3</a>). <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> documented healing rates for participants on continuous daily PPI versus placebo (i.e. abrupt discontinuation). Based on healing rates reported, we calculated relapse rates (the inverse) and interpreted them as a marker for ADWE (<a href="./references#CD011969-fig-0009" title="">Analysis 2.2</a>). Overall, 69.6% of participants with a history of esophagitis had a relapse with abrupt discontinuation compared to 20.4% with continuous treatment. </p> </section> <section id="CD011969-sec-0089"> <h5 class="title">Participant satisfaction</h5> <p>Five studies (n = 1653) evaluated participant satisfaction with on‐demand deprescribing as compared to continuous daily PPI use (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>). Participant satisfaction was interpreted using unwillingness to continue (based on premature discontinuation rates) and inadequate symptom relief (<a href="./references#CD011969-fig-0007" title="">Analysis 1.4</a>). In these studies, participants using PPIs on‐demand had a greater likelihood of being dissatisfied with therapy compared to participants using PPIs continuously (15.8% with on‐demand versus 8.8% with continuous; RR 1.82, 95% CI 1.26 to 2.65). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011969-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011969-sec-0090"></div> <section id="CD011969-sec-0091"> <h3 class="title" id="CD011969-sec-0091">Summary of main results</h3> <p>This systematic review summarized the data from six RCTs looking at deprescribing of PPIs versus continuation of chronic daily PPI therapy (<a href="./full#CD011969-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011969-tbl-0002">summary of findings Table 2</a>). Five trials assessed on‐demand therapy and one trial evaluated the effects of abrupt PPI discontinuation. The majority of the participants had mild GERD with or without low‐grade esophagitis. Our results show an increase in lack of symptom control and participant dissatisfaction with on‐demand deprescribing, though there was a significant reduction in pill use and burden (MD 3.79 pills weekly). Independent of the method of deprescribing, the risk of being dissatisfied with the control of upper GI symptoms was higher in the deprescribing arms. Despite these findings, a proportion of participants tolerated on‐demand therapy, though further studies are required to identify which subpopulation may benefit the most, without putting them at risk of ADWE as was seen with the <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> and <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> trials. It also remains unclear whether deprescribing is effective and safe in people with severe esophagitis, as this population was not captured in the included trials. Unfortunately, we found no trials to satisfy our primary and secondary outcomes of cost and PDWEs. </p> <section id="CD011969-sec-0092"> <h4 class="title">On‐demand proton pump inhibitor deprescribing</h4> <p>Five trials evaluated deprescribing via an on‐demand approach (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0006" title="Van derVeldenAW , deWitNJ , QuarteroAO , GrobbeeDE , NumansME . Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion2010;81(1):43‐52. ">Van der Velden 2010</a>). Participants were aged 48 to 57 years and either had NERD or a milder form of esophagitis (LA grade A and B or Savary‐Miller grade 1 and 2). </p> <p>For the primary outcome of change in upper GI symptoms, deprescribing demonstrated a return of symptoms (e.g. heartburn, regurgitation) for a proportion of people. These results were expected as participants in the on‐demand group were instructed to initiate on‐demand PPI use upon sensation of symptoms. In the combined cohort of 1653 participants randomized to on‐demand therapy, approximately 16.3% had either treatment failure or inadequate symptom relief (compared to around 9.2% on continuous PPI therapy, P less than 0.0001). This indicates that while the risk of recurrent symptoms with on‐demand therapy is greater than continuous daily PPI use, the majority of people will still tolerate the intervention. Further studies are required to identify which subpopulations comprise this group. </p> <p>We pooled data for drug burden/PPI use from three on‐demand trials (n = 1152) (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>; <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>; <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>). The pooled data favored deprescribing (MD 3.79 pills weekly) and was statistically significant with a P value of less than 0.00001, although heterogeneity was high. The pooled results of this review were consistent with what is currently published in primary literature. Trials evaluating on‐demand PPI use have reported a mean pill consumption of 0.3 pills per day (<a href="./references#CD011969-bbs2-0017" title="BigardMA , GenestinE . Treatment of patients with heartburn without endoscopic evaluation: on‐demand treatment after effective continuous administration of lansoprazole 15 mg. Alimentary Pharmacology &amp; Therapeutics2005;22(7):635‐43. ">Bigard 2005</a>; <a href="./references#CD011969-bbs2-0052" title="KaspariS , KupcinskasL , HeinzeH , BerghöferP . Pantoprazole 20 mg on demand is effective in the long‐term management of patients with mild gastro‐oesophageal reflux disease. European Journal of Gastroenterology &amp; Hepatology2005;17(9):935‐41. ">Kaspari 2005</a>; <a href="./references#CD011969-bbs2-0129" title="PaceF , Bianchi PorroG . On‐demand PPI therapy in GERD. Current Treatment Options in Gastroenterology2008;11:35‐42. ">Pace 2008</a>; <a href="./references#CD011969-bbs2-0065" title="PonceJ , ArgüelloL , BastidaG , PonceM , OrtizV , GarriguesV . On‐demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health‐related quality of life, and patient satisfaction. Digestive Diseases and Sciences2004;49(6):931‐6. ">Ponce 2004</a>; <a href="./references#CD011969-bbs2-0079" title="TsaiHH , ChapmanR , ShepherdA , McKeithD , AndersonM , VearerD , et al. Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study. Alimentary Pharmacology &amp; Therapeutics2004;20(6):657‐65. ">Tsai 2004</a>). </p> <p>Participant satisfaction was determined by evaluating unwillingness to continue treatment and inadequate symptom relief. Data for this outcome favored chronic PPI use. Interestingly, when assessed individually, not all trials showed a significant difference in participant satisfaction ratings between groups. <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>, <a href="./references#CD011969-bbs2-0002" title="BourB , StaubJ‐L , ChoustermanM , LabayleF , NaletB , NouelO , et al. Long‐term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on‐demand treatment compared with continuous treatment. Alimentary Pharmacology &amp; Therapeutics2005;21(7):805‐12. ">Bour 2005</a>, and <a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a> had CI value crossing one; however, the overall treatment effect showed significance in favor of deprescribing (RR 1.82, 95% CI 1.26 to 2.65, P &lt; 0.002). One on‐demand PPI trial provided data for unwillingness to continue secondary to inadequate relief, which was interpreted for this review as a marker for participant dissatisfaction (and thus the inverse, as participant satisfaction) (<a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>). The open‐label nature of <a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a> likely influenced the results as participants were aware that they were in control of PPI use and likely favored this method rather than daily PPI use. In past literature, participant satisfaction has been reported to be in favor of chronic PPI use, though the difference from on‐demand therapy is small (<a href="./references#CD011969-bbs2-0128" title="PaceF , NegriniC , WiklundI , RossiC , SavarinoV . Quality of life in acute and maintenance treatment of non‐erosive and mild erosive gastro‐oesophageal reflux disease. Alimentary Pharmacology &amp; Therapeutics2005;22:349‐56. ">Pace 2005</a>). Our results parallel data that have been previously published. We believe that on‐demand therapy could be a viable option for people with NERD or mild‐to‐moderate GERD, without compromising satisfaction of symptom control. Further studies using more targeted measurements of participant satisfaction are needed to confirm or refute these results. </p> <p>One on‐demand trial had data for ADWE (<a href="./references#CD011969-bbs2-0001" title="BayerdörfferE , BigardMA , WeissW , MearinF , RodrigoL , MunozJED , et al. Randomized, multicenter study: on‐demand versus continuous maintenance treatment with esomeprazole in patients with non‐erosive gastroesophageal reflux disease. BMC Gastroenterology2016;16(48):1‐12. ">Bayerdörffer 2016</a>). Participants in this trial were assessed endoscopically before and after randomization. Those who did not present with esophagitis were included and randomized. Investigators performed an endoscopy at the end of the trial to assess the development of esophagitis. It found that 5% (n = 15) of participants using on‐demand PPI developed mild esophagitis (14 with LA grade A, 1 with grade B). </p> </section> <section id="CD011969-sec-0093"> <h4 class="title">Abrupt discontinuation deprescribing</h4> <p>We identified one trial of abrupt discontinuation (<a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a>). Participants in this trial experienced mild‐to‐moderate esophagitis (Grade 1 or 2), though they were much older than participants taking on‐demand therapy (mean age 73 years). This trial demonstrated a statistically significant increase in the primary outcome of lack of symptom control. Participants experienced return of symptoms, which is expected, as transient and reversible rebound effects have been previously described for both healthy people and people with GI disorders upon abrupt PPI discontinuation (<a href="./references#CD011969-bbs2-0135" title="ReimerC , SondergaardB , HilstedL , BytzerP . Proton‐pump inhibitor therapy induces acid‐related symptoms in health volunteers after withdrawal of therapy. Gastroenterology2009;137(1):80‐7. ">Reimer 2009b</a>). Once again, symptom relapse was not observed in the entire cohort (67.9% in abrupt discontinuation versus 22.4% in the continuous arm), suggesting almost a third of the studied population tolerated abrupt discontinuation. </p> <p>The <a href="./references#CD011969-bbs2-0005" title="PilottoA , LeandroG , FranceschiM , Ageing and Acid‐Related Disease Study Group. Short‐ and long‐term therapy for reflux oesophagitis in the elderly: a multi‐centre, placebo‐controlled study with pantoprazole. Alimentary Pharmacology &amp; Therapeutics2003;17(11):1399‐406. ">Pilotto 2003</a> trial also addressed the secondary outcome of ADWEs. The trial evaluated changes in endoscopic findings (i.e. healing rates), which were interpreted within this review as relapse rates by assuming the inverse. The results from this trial indicated an increased risk of ADWE with deprescribing (i.e. abrupt discontinuation) that was statistically significant in people with esophagitis grades 1 or 2. Despite these findings, it is difficult to make any conclusions as the results are based on a single study of older adults with mild‐to‐moderate disease. Furthermore, the trial had a small sample size with no reported power or predefined primary endpoints. Current recommendations also suggest avoiding abrupt discontinuation, as relapse acid hypersecretion has been demonstrated even in healthy participants (<a href="./references#CD011969-bbs2-0135" title="ReimerC , SondergaardB , HilstedL , BytzerP . Proton‐pump inhibitor therapy induces acid‐related symptoms in health volunteers after withdrawal of therapy. Gastroenterology2009;137(1):80‐7. ">Reimer 2009b</a>). Other potential ADWEs such as upper GI bleeding or progression of esophagitis to Barrett's esophagus, among others, were not addressed by any of the trials included. </p> </section> </section> <section id="CD011969-sec-0094"> <h3 class="title" id="CD011969-sec-0094">Overall completeness and applicability of evidence</h3> <p>The evidence for PPI use in many indications (e.g. GERD, PUD, SUP) only supports short‐term use (e.g. two to 12 weeks), yet these drugs are commonly continued for prolonged periods or even indefinitely, without appropriate reassessment (<a href="./references#CD011969-bbs2-0103" title="DonnellanC , PrestonC , MoayyediP , SharmaN . Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews2004, issue 4:CD003245. [DOI: 10.1002/14651858.CD003245.pub2] ">Donnellan 2004</a>; <a href="./references#CD011969-bbs2-0134" title="ReimerC , BytzerP . Clinical trial: long‐term use of proton pump inhibitors in primary care patients ‐ a cross sectional analysis of 901 patients. Alimentary Pharmacology &amp; Therapeutics2009;30(7):725‐32. ">Reimer 2009a</a>). Continuous use of PPIs for durations exceeding accepted standards appears to be commonplace, and is likely due to the fact that this class of medication is very well tolerated and considered benign compared to other prescribed medications. This relatively desirable safety profile often overshadows lesser known drug interactions (e.g. hepatic enzyme inhibition, effects on drug absorption or activation) and poorly understood adverse effects and associated risks (vitamin B<sub>12</sub> deficiency, hypomagnesemia, CAP, <i>C. difficile</i> infection, diarrhea, headache, and fractures) (<a href="./references#CD011969-bbs2-0091" title="AmentPW , DicolaDB , JamesME . Reducing adverse effects of proton pump inhibitors. American Family Physician2012;86(1):66‐70. ">Ament 2012</a>; <a href="./references#CD011969-bbs2-0098" title="ChubinehS , BirkJ . Proton pump inhibitors: the good, the bad, and the unwanted. Southern Medical Journal2012;105(11):613‐8. ">Chubineh 2012</a>; <a href="./references#CD011969-bbs2-0104" title="FohlAL , RegalRE . Proton pump inhibitor‐associated pneumonia: not a breath of fresh air after all?. World Journal of Gastrointestinal Pharmacology and Therapeutics2011;2(3):17‐26. ">Fohl 2011</a>; <a href="./references#CD011969-bbs2-0123" title="LinskyA , SimonSR . Reversing gears: discontinuing medication therapy to prevent adverse events. JAMA Internal Medicine2013;173(7):524‐5. ">Linsky 2013</a>). Although these adverse effects may not be very common and true association with risk is debatable, the extensive use of PPIs in a wide range of populations without monitoring and reassessment is concerning. </p> <p>The six trials included in this review mimic real world practice as they assessed people with adequate control and symptom relief on chronic daily PPI therapy. The control arm of no change in current daily PPI dose reflects the all too common decision of practitioners and people not to change therapy deemed effective. The deprescribing arms of abrupt discontinuation or on‐demand PPI use represent two of the many options practitioners and people have to minimize medication use and actual or potential adverse effects of chronic PPI therapy. </p> <p>Unfortunately, the search identified insufficient trials to thoroughly investigate the benefits and harms of deprescribing PPIs. As described in the <a href="#CD011969-sec-0030">Background</a> section of this review, there are many other methods of deprescribing that were not captured here. There were also no trials that investigated our primary outcome of burden/resource use, and secondary outcome of PDWE. The systematic review identified many gaps in literature that still need to be addressed. Our literature search captured predominantly people with NERD or mild esophagitis (LA grade A and B, Savary‐Miller grade 1 and 2), which limits the generalizability of results. Outcomes such as PDWE and ADWE are also not well addressed in the literature. In addition, the optimal approach to deprescribing PPIs has not been evaluated (e.g. tapering before stopping). Studies employed different definitions of symptom relapse and participant satisfaction; consistency would be helpful to improve the quality of the body of evidence and should include participant perspective in terms of what is meaningful to them. The data presented in this systematic review were not conclusive; further studies are required to address the gaps in literature. </p> </section> <section id="CD011969-sec-0095"> <h3 class="title" id="CD011969-sec-0095">Quality of the evidence</h3> <p>The quality and strength of the evidence was assessed using the GRADE system (<a href="./references#CD011969-bbs2-0110" title="GRADE Working Group, McMaster University. GRADEpro. Version accessed 7 December 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro</a>). Overall, the quality of evidence for on‐demand PPI use was very low to moderate. There was serious risk of bias for all outcomes. The quality for the outcome of lack of symptom control was low due to serious imprecision. The quality of evidence for pill use was moderate. Lastly, participant satisfaction evidence was very low in quality due to serious indirectness and imprecision. This further highlights the need for future studies to address the clinical benefits and harms of PPI deprescribing. The quality of the evidence for the abrupt discontinuation deprescribing method was very low due to high risk of bias and wide CIs. </p> </section> <section id="CD011969-sec-0096"> <h3 class="title" id="CD011969-sec-0096">Potential biases in the review process</h3> <p>While we attempted to adhere to sound methodology, this systematic review was not void of limitations. First, as deprescribing is not widely described in the scientific literature, there was potential of not capturing all relevant trials. Although we sought assistance from a specialist librarian to create a filter to capture all trials related to deprescribing, it remained, nonetheless, an unvalidated search strategy. Ideally, a grey literature search would have created a more comprehensive review, however, funding and resources did not allow for this to be investigated. Second, few trials were available to confidently support the objective of this study. This could be due to the strict criteria outlined for the control arm. To satisfy the requirement for a control arm, only RCTs with a minimum run‐in phase of 28 days were considered to fulfil the definition of "chronic PPI use". This criterion was essential to capture true chronic daily PPI users. Additionally, even though eligibility criteria were broad for participants, the trials captured in this systematic review included predominantly people with NERD and mild‐to‐moderate GERD which limits the generalizability of results. All trials were of short duration (less than one year). As such, the long‐term benefits or harms of deprescribing PPIs in chronic users are difficult to extrapolate. </p> </section> <section id="CD011969-sec-0097"> <h3 class="title" id="CD011969-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>Previous publications outline deprescribing methods for PPIs (<a href="./references#CD011969-bbs2-0148" title="ZarowitzB . The challenge of discontinuing proton pump inhibitors. Geriatric Nursing2011;32(4):276‐8. ">Zarowitz 2011</a>); however, there is very little evidence comparing deprescribing modalities to continuous daily PPI use. </p> <p>With respect to on‐demand therapy, a large body of evidence supports this deprescribing alternative for people with milder forms of GERD (NERD and uninvestigated GERD) (<a href="./references#CD011969-bbs2-0019" title="BytzerP , BlumA , DeHerdtD , DuboisD . Six‐month trial of on‐demand rabeprazole 10 mg maintains symptom relief in patients with non‐erosive reflux disease. Alimentary Pharmacology &amp; Therapeutics2004;20(2):181‐8. ">Bytzer 2004</a>; <a href="./references#CD011969-bbs2-0121" title="LeeTJ , FennertyMB , HowdenCW . Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease?. Alimentary Pharmacology &amp; Therapeutics2004;20(11‐12):1241‐51. ">Lee 2004</a>; <a href="./references#CD011969-bbs2-0004" title="MorganDG , O'MahonyMFJ , O'MahonyWF , RoyJ , CamachoF , DinniwellJ , et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on‐demand therapy with rabeprazole 20 mg. Canadian Journal of Gastroenterology2007;21(12):820‐6. ">Morgan 2007</a>; <a href="./references#CD011969-bbs2-0147" title="ZacnyJ , ZamakhsharyM , SketrisI , Veldhuyzen van ZantenS . Systematic review: the efficacy of intermittent and on‐demand therapy with histamine H2‐receptor antagonists or proton pump inhibitors for gastro‐oesophageal reflux disease patients. Alimentary Pharmacology &amp; Therapeutics2005;21:1299‐312. ">Zacny 2005</a>). One systematic review assessing intermittent and on‐demand acid suppression therapy (e.g. H<sub>2</sub>RA and PPI) concluded that in people with mild GERD, first treated for four to eight weeks with continuous PPI, a six‐month course of on‐demand therapy was efficacious (<a href="./references#CD011969-bbs2-0147" title="ZacnyJ , ZamakhsharyM , SketrisI , Veldhuyzen van ZantenS . Systematic review: the efficacy of intermittent and on‐demand therapy with histamine H2‐receptor antagonists or proton pump inhibitors for gastro‐oesophageal reflux disease patients. Alimentary Pharmacology &amp; Therapeutics2005;21:1299‐312. ">Zacny 2005</a>). Of these participants, 70% to 93% were willing to continue treatment with a deprescribing regimen. A more recent Danish review by <a href="./references#CD011969-bbs2-0113" title="HaastrupP , PaulsenM , BegtrupL , HansenJ , JarbolD . Strategies for discontinuation of proton pump inhibitors: a systematic review. Family Practice2014;31(6):625‐30. ">Haastrup 2014</a> described six clinical trials (RCT and non‐RCT), using different deprescribing methods (e.g. discontinuation, dose reduction). Indication for PPI use was unknown in two trials, and described as GERD or nonulcer dyspepsia in the remaining four trials. The authors reported PPI discontinuation without deteriorating symptom control ranging from 14% to 64%, with durations of up to one year or more, similar to results of this trial (approximately a third tolerated abrupt discontinuation and 85% tolerated stepdown to on‐demand therapy) (<a href="./references#CD011969-bbs2-0113" title="HaastrupP , PaulsenM , BegtrupL , HansenJ , JarbolD . Strategies for discontinuation of proton pump inhibitors: a systematic review. Family Practice2014;31(6):625‐30. ">Haastrup 2014</a>). </p> <p>Another RCT assessed symptom relief in people with GERD treated with on‐demand omeprazole versus continuous therapy (<a href="./references#CD011969-bbs2-0060" title="NagaharaA , HojoM , AsaokaD , SasakiH , WatanabeS . A randomized prospective study comparing the efficacy of on‐demand therapy versus continuous therapy for 6 months for long‐term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan. Scandinavian Journal of Gastroenterology2014;49(4):409‐17. ">Nagahara 2014</a>). Their results indicated that a greater proportion of people with on‐demand treatment had symptom relief by 24 weeks (74% with on‐demand therapy versus 66.7% continuous therapy), though this was not statistically significant. They concluded that on‐demand treatment in people with NERD would be adequate maintenance therapy and that continuous therapy would be ideal for people with reflux esophagitis. </p> <p>To date, we identified a single meta‐analysis by Jiang and colleagues designed to compare on‐demand PPI use versus once‐daily PPI therapy (<a href="./references#CD011969-bbs2-0118" title="JiangY‐X , ChenY , KongX , TongY‐L , XuS‐C . Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on‐demand: a meta‐analysis. Hepato‐gastroenterology2013;60(125):1077‐82. ">Jiang 2013</a>). This study included two RCTs (<a href="./references#CD011969-bbs2-0003" title="JanssenW , MeierE , GatzG , PfaffenbergerB . Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: once‐daily treatment in the acute phase, and comparison of on‐demand versus continuous treatment in the long term. Current Therapeutic Research, Clinical and Experimental2005;66(4):345‐63. ">Janssen 2005</a>; <a href="./references#CD011969-bbs2-0079" title="TsaiHH , ChapmanR , ShepherdA , McKeithD , AndersonM , VearerD , et al. Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND Study. Alimentary Pharmacology &amp; Therapeutics2004;20(6):657‐65. ">Tsai 2004</a>; n = 1054). Participants were approximately 50 to 52 years of age and were diagnosed with NERD or GERD classified as Savary‐Miller grade 1. The authors concluded that on‐demand therapy was more effective (i.e. greater proportion of people willing to continue with on‐demand therapy) than daily PPI use. </p> <p>Our systematic review differed in that we investigate further, and aim to assess both the efficacy and safety, and identify potential benefits and harms of deprescribing PPIs. Our results indicated the opposite of what was published by Jiang and colleagues in that a significant proportion of participants in the on‐demand group were unwilling to continue due to return of GI symptoms. This discrepancy identified gaps in literature, and further trials are required to assess the efficacy, safety, benefits, and harms of deprescribing PPIs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011969-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. NSAID: nonsteroidal anti‐inflammatory drug; PPI: proton pump inhibitor; RCT: randomized controlled trial." data-id="CD011969-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. NSAID: nonsteroidal anti‐inflammatory drug; PPI: proton pump inhibitor; RCT: randomized controlled trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD011969-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD011969-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 1 Lack of symptom control." data-id="CD011969-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 1 Lack of symptom control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 2 Pill use." data-id="CD011969-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 2 Pill use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 3 Adverse drug withdrawal event." data-id="CD011969-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 3 Adverse drug withdrawal event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 4 Participant satisfaction." data-id="CD011969-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use, Outcome 4 Participant satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Abrupt discontinuation proton pump inhibitor (PPI) deprescribing versus continued use, Outcome 1 Lack of symptom control." data-id="CD011969-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Abrupt discontinuation proton pump inhibitor (PPI) deprescribing versus continued use, Outcome 1 Lack of symptom control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011969-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/urn:x-wiley:14651858:media:CD011969:CD011969-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_t/tCD011969-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Abrupt discontinuation proton pump inhibitor (PPI) deprescribing versus continued use, Outcome 2 Adverse drug withdrawal events." data-id="CD011969-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Abrupt discontinuation proton pump inhibitor (PPI) deprescribing versus continued use, Outcome 2 Adverse drug withdrawal events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/media/CDSR/CD011969/image_n/nCD011969-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011969-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">On‐demand deprescribing compared to continued use for people with moderate GERD and mild esophagitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>On‐demand deprescribing compared to continued use for people with moderate GERD and mild esophagitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with moderate GERD and mild esophagitis, mean age 48 to 57 years<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> on‐demand deprescribing<br/> <b>Comparison:</b> continued use </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Continued use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> On‐demand deprescribing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Lack of symptom control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.71</b> <br/> (1.31 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1653<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> <br/> (120 to 203) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> <br/> (161 to 272) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pill use (pills/week)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pill use (pills/week) in the intervention groups was<br/> <b>3.79 lower</b> <br/> (4.73 to 2.84 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1152<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost/resource use</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>We found no data on cost or resource use.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse drug withdrawal events ‐ esophagitis (endoscopic findings)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 30.59</b> </p> <p>(1.84 to 508.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>598<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk not estimable as no events in continued use arm.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.82</b> <br/> (1.26 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1653<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (111 to 234) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>147 per 1000</b> <br/> (102 to 215) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>GERD:</b> gastroesophageal reflux disease; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to a high risk of detection bias, and attrition bias.<br/> <sup>2</sup> Downgraded one level due to wide confidence intervals and summary statistic close to the line of no effect.<br/> <sup>3</sup> Downgraded one level due to high risk of detection and attrition bias.<br/> <sup>4</sup> Downgraded one level due to high risk of attrition and reporting bias.<br/> <sup>5</sup> Downgraded one level due to indirectness as poor methods of satisfaction used (willingness to continue or "inadequate relief"). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">On‐demand deprescribing compared to continued use for people with moderate GERD and mild esophagitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011969-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Abrupt discontinuation deprescribing compared to continued use for people with mild‐to‐moderate esophagitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Abrupt discontinuation deprescribing compared to continued use for people with mild to moderate esophagitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild to moderate esophagitis, symptomatic, aged &gt; 18 years (mean age 73 years)<br/> <b>Settings: o</b> utpatient<br/> <b>Intervention:</b> abrupt discontinuation deprescribing<br/> <b>Comparison:</b> continued use </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Continued use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Abrupt discontinuation deprescribing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Lack of symptom control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.02</b> <br/> (1.74 to 5.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>105<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>678 per 1000</b> <br/> (391 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>225 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>679 per 1000</b> <br/> (392 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse drug withdrawal events ‐ relapse (endoscopic findings)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.41</b> <br/> (1.91 to 6.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>105<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>696 per 1000</b> <br/> (390 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>696 per 1000</b> <br/> (390 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to concerns surrounding attrition bias and blinding.<br/> <sup>2</sup> Downgraded two levels due to wide confidence intervals, and small number of participants and events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Abrupt discontinuation deprescribing compared to continued use for people with mild‐to‐moderate esophagitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/full#CD011969-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011969-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Lack of symptom control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.31, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Treatment failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.21, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Inadequate symptom relief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.15, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pill use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.79 [‐4.73, ‐2.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse drug withdrawal event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Esophagitis (endoscopic findings)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participant satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.26, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Unwilling to continue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.14, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Inadequate relief</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.25, 2.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">On‐demand proton pump inhibitor (PPI) deprescribing versus discontinued use</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011969-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Abrupt discontinuation proton pump inhibitor (PPI) deprescribing versus continued use</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Lack of symptom control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Symptom relapse rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse drug withdrawal events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Relapse (endoscopic findings)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Abrupt discontinuation proton pump inhibitor (PPI) deprescribing versus continued use</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011969.pub2/references#CD011969-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011969.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011969-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011969-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011969-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011969-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011969-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011969-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011969\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011969\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011969\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011969\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011969\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=gpg7sF9V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011969.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011969.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011969.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011969.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011969.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719489086"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011969.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719489089"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011969.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de9ffc8cb9373',t:'MTc0MDcxOTQ4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 